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PHARMACODYNAMICS OF TOPICAL GLUCOCORTICOIDS 
Abstract
The efficiency of topical drug delivery is notoriously poor, with typical 
bioavailabilities of only a few percent of the applied dose. A major reason for 
this disappointing situation is the absence of a quantitative and validated 
methodology (apart from the vasoconstrictor assay for topical 
glucocorticoids) with which to quantify the rate and extent of drug delivery to 
a target into the skin. In an attempt to address this situation, significant efforts 
are being directed to the dermatopharmacokinetic (DPK) approach using 
tape-stripping.
The main objective of this thesis, therefore, was to compare the in vivo 
bioavailability profiles of betamethasone 17-valerate (BMV) assessed using 
the vasoconstrictor assay and the DPK approach. Furthermore, the ability of 
these two methods to distinguish between different formulations as well as 
different concentrations was examined. As the DPK approach is currently 
under critical re-evaluation, different cleaning procedures of the skin before 
tape-stripping were compared and evaluated. Moreover, the influence of the 
viscosity of the formulation on the DPK results was also determined. In 
addition, the effect of the vehicles on skin hydration was studied.
Applying different BMV concentrations resulted in a clear 
concentration dependence of the skin blanching response until saturation of 
the response occurred. Upon this saturation effect, any changes between 
different formulations and between concentrations could no longer be 
observed. Due to the saturable nature of the skin blanching response, the 
interpretation of the data has to be considered with care and, therefore, it is 
important to operate in the linear part of the ‘dose-response’ curve, whenever 
quantitative conclusions about bioavailability are to be drawn. The DPK 
approach, on the other hand, showed reasonable reproducibility and 
distinguished clearly between different formulations and different BMV 
concentrations applied; it appears to offer a reliable metric, therefore, with
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which to quantify topical bioavailability. The cleaning procedure, as well as 
the viscosity of the formulation applied, have a significant influence on the 
apparent extent of drug delivery into the stratum corneum. Excess 
formulation, especially from semi-solids, may be trapped in the skin ‘furrows’ 
and requires an efficient skin cleaning procedure to ensure its complete 
removal.
Overall, the DPK technique merits continued evaluation and 
optimization as a tool for the quantification of topical bioavailability and 
bioequivalence. These steps are essential for the ultimate objective of 
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Topical glucocorticoids (TG) are the most frequently prescribed drugs 
by dermatologists. Their clinical effectiveness in the treatment of psoriasis 
and atopic dermatitis is related to their vasoconstrictive, anti-inflammatory, 
immunosuppressive and antiproliferative effects. Treatment with TG 
formulations is effective, easy to administer, acceptable to patients and safe 
when used correctly. This review focuses on the main factors influencing the 
effectiveness and bioavailability of TG namely (i) the structure of the skin 
barrier, (ii) effects and side-effects of TG, (iii) chemical modifications in the 
TG structure, (iv) vehicle or formulation effects, and (v) methods to determine 
bioavailability and/or bioequivalence (BA/BE).
2. The skin barrier
The skin is the largest organ of the body with an area of approximately 
2 m2 and is the interface between the organism and its environment. It 
prevents the loss of water and the ingress of foreign materials. In essence, 
the skin consists of three functional layers: the epidermis, the dermis (corium) 
and the hypodermis. The hypodermis is a subcutaneous tissue consisting of 
fat and muscle and acts as a heat isolator, a shock absorber, and an energy 
storage region. The dermis is ~ 2 mm thick and contains collagen, elastic 
fibres, blood vessels, nerves as well as hair follicles and sebaceous and 
sweat glands. The main cells in the dermis are fibroblasts, which are involved 
in the immune and inflammatory response and upon which glucocorticoid 
receptors are found. The dermis is the source of nutrients for the epidermis. 
Because the epidermis is avascular, essential substances are transported 
only by passive diffusion. The epidermis has a multilayered structure 
reflecting different stages of differentiation of the skin cells (the 
keratinocytes). From the proliferative, basal layer, the cells change in an 
ordered fashion from metabolically active and dividing to dense, functionally 
dead, and fully keratinised, the so-called corneocytes. These corneocytes are 
embedded in a lipid matrix and form the outer 10 - 20 pm of the epidermis, 
the stratum corneum (SC) [1].
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The cytoplasm of cultured human skin keratinocytes and fibroblasts 
contains macromolecules that bind glucocorticoids with high affinity, 
suggesting that the sites of action for TG are both epidermal and dermal cells 
[2,3]. To reach these target cells, TG have to permeate the SC (Figure 1), 
which contributes the major barrier to percutaneous absorption [4,5].
Cornified cell Natural moisturizing
envelope (CE) Corneodesmosome factor (NMF)
I  0 o
n r V~
CorneocyteIntercellullar Keratin
lamellar lipids microfibrillar matrix
Figure 1: Schematic ‘bricks and mortar’ representation of the structural and 
functional components of the SC. Modified from Harding [6],
The terminally differentiated corneocytes (bricks) consist primarily of a 
highly organized keratin microfibrillar matrix, which provides mechanical 
resistance. Natural moisturizing factor (NMF), a mixture of amino acids, lactic 
acid, urea, citrate and sugar, is present at a high level in the corneocytes and 
acts as a very efficient humectant [7]. In addition, protein junctions, the 
corneodesmosomes, link adjacent corneocytes and ensure the cohesiveness 
of this layer [26-28], During the formation and maturation of the SC, 
desmosomes are modified and their number decreases towards the skin 
surface [27,28]. Each corneocyte is surrounded by a 15 - 20 nm thick protein 
shell -  the cornified cell envelope (CE), a 15 nm layer of defined structural 
proteins and a 5 nm thick layer of specialized lipids. The lipid monolayer 
provides a hydrophobic interface between the CE itself and SC lipid lamellae 
and helps maintain water barrier function [8,9]. While typical biological
11
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membranes are mainly composed of phospholipids, the intercellular SC lipids 
(mortar) comprise primarily ceramides (~ 40 % w/w), free fatty acids (~ 10 % 
w/w) and cholesterol (~ 25 % w/w), together with a small fraction of 
cholesterol sulfate and triglycerides (Figure 2) [10-13], The lipids originate 
from lamellar bodies that are synthesized in the upper viable layers of the 
epidermis, which are ultimately secreted from the cells into the intercellular 
space. These lipids, which are organized in multilamellar bilayers, regulate 
the passive flux of water through the SC and are considered to be very 
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Figure 2: Basic structures of SC lipids: free fatty acids (FF), triglycerides
(TAG), ceramides (Cer), cholesterol (Ch), cholesterol sulfate (ChS).
Nine classes of ceramides have been recognized and differ from each 
other by the head group architecture and by the average fatty acid chain 
length [20,21], Ceramides 1 and 9 are believed to be particularly important
12
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[22-24]. A direct relationship between the degree of barrier perturbation 
(measured as transepidermal water loss) and the amount of SC lipid 
removed has been demonstrated [25].
This ‘brick and mortar’ arrangement of the SC creates a tortuous route 
for compounds to permeate the barrier.
3. Percutaneous absorption and mechanism of TG action
The percutaneous absorption of a drug from a topically applied 
formulation is a complex process [26]. The physicochemical characteristics of 
the drug and the vehicle and the physiological conditions of the skin can 
significantly affect percutaneous absorption. For a topically applied 
formulation containing a glucocorticoid the percutaneous absorption involves 
the following steps:
(a) release from the formulation,
(b) penetration into the skin’s outermost layer, the SC and 
permeation/diffusion through the SC,
(c) partitioning from the SC into the viable epidermis and the 
dermis,
(d) within the viable epidermis/dermis, diffusion to reach the 
glucocorticoid receptor.
Penetration into the SC is assumed to be the rate-limiting step for 
percutaneous absorption of TG. In this case, the glucocorticoid amount 
reaching the target cell will be determined by its partitioning into and rate of 
transport through the SC. These processes are greatly influenced by the 
physicochemical properties of both the drug and the vehicle [27,28]. The in 
vivo clinical effectiveness of a TG formulation depends on the bioavailability 
of the glucocorticoid within the skin at the site of action. For TG the target 
cells are the keratinocytes and fibroblasts within the viable epidermis and 
dermis, where the glucocorticoid receptors are located [2,29]. Having 
attained the target, the cellular uptake and residence time of the steroid as 
well as its affinity for the glucocorticoid receptor will determine the clinical 
effect [3,30-32]. From studies with cultured human fibroblasts and 
keratinocytes, the cellular uptake of glucocorticoids has been shown to be a
13
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non-mediated, passive diffusion process that involves two intrinsic steps: a 
rapid, non-specific, high-capacity association to the cell membrane followed 
by a slower process leading to strong binding of glucocorticoid within the cell 
[31]. The total uptake of steroid by fibroblasts and keratinocytes was related 
to drug lipophilicity. Although, as stated, steroids are generally thought to be 
transported across the cell membrane by passive diffusion, there is some 
evidence that certain target cells possess a specific transport system for 
these compounds [33]. The anti-inflammatory and immunosuppressive 
effects of TG seem to be mediated largely by regulation of corticosteroid- 
responsive genes. Within the cytoplasm, the steroid binds to the 
glucocorticoid receptor, forming a complex that is rapidly transported to the 
nucleus. The glucocorticoid-receptor complex inside the nucleus then binds 
to a region of DNA called the glucocorticoid responsive element to either 
stimulate or inhibit transcription and regulate thereby the inflammatory 
process [34,35].
In addition to this direct regulatory effect on gene transcription, TG are 
also able to indirectly regulate transcription by blocking the effects of other 
transcription factors, such as nuclear factor-kappa B alpha [36,37].
TG may inhibit the transcription of proinflammatory cytokine genes 
(including the interleukins IL-1, IL-2, IL-6, interferon gamma, and tumour 
necrosis factor-alpha genes), T-cell proliferation, and T-cell dependent 
immunity [38]. In fibroblasts, IL-1 a is responsible for proliferation, 
collagenase induction, and IL-6 synthesis, which control skin thickness [39]. 
The inhibition of IL-1 a in keratinocytes has anti-inflammatory effects, 
whereas the same inhibition in fibroblasts has antiproliferative and 
atrophogenic effects. The vasoconstrictive effect of TG may contribute to 
their anti-inflammatory activity, diminishing erythema at the lesion site. 
However, the exact mechanism is not completely clear.
Finally, clinical efficacy is self-evidently and significantly influenced by 
corticosteroid structure, the formulation and the applied concentration of the 




Despite their clear benefit in the therapy of inflammatory disease, TG 
are associated with a number of side-effects that limit their use. One 
particularly important local side-effect is epidermal thinning or atrophy [45]. 
This effect can start after 3 to 14 days of corticosteroid treatment with 
microscopic degenerative changes in the epidermis, including reduction in 
cell size and number of cell layers [34,46]. TG inhibit epidermal cell 
differentiation by inhibition of keratinocyte proliferation and acceleration of 
keratinocyte maturation [47-49].
Moreover, prolonged TG therapy increases basal transepidermal 
water loss, indicating an effect on permeability barrier function [46]. This 
change has been associated with a decrease in SC thickness, a reduction in 
lipid content [46], a decrease in the number of lamellar bodies [48] and in the 
number of intercellular lamellae (although the structure of these lipid bilayers 
appeared normal [46]).
Even short-term treatment with a potent TG, clobetasol (0.05 % w/V), 
applied once a day for 3 days can alter epidermal structure and function in 
humans [50]. SC barrier recovery was significantly delayed, even though 
visible changes in the epidermis were not observed [50]. In hairless mouse 
skin, the same short term treatment inhibited epidermal cholesterol, fatty 
acid, and ceramide synthesis by more than 50 %. This inhibition may account 
for the decreased production and secretion of lamellar bodies and the 
impaired formation of lipid bilayers in the SC and the resulting abnormality in 
barrier function [50]. TG also exerted negative effects on the integrity and 
cohesion of the SC owing to a reduction in the number of 
corneodesmosomes in the SC [50].
Furthermore, histological changes are observed in the dermis. Dermal 
atrophy results from the direct antiproliferative action of TG on fibroblasts 
[51]; in turn, this leads to a reduction in the synthesis of collagen and 
mucopolysaccharides and a loss of dermal support. The elastin fibres in the 
upper layers of the dermis become thin and fragmented, while the deeper 
fibres collapse to form a compact and dense network. As a result of this thin
15
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and brittle skin, there is local vascular dilatation, which is responsible for 
striae, telangiectasia, and purpura [34,52].
Systemic side-effects of TG, such as pituitary-adrenal axis 
suppression, are rare but have to be seriously considered when treating 
children because of the potential for growth retardation. Furthermore, 
children have a higher ratio of total body surface area to body weight (about 
2.5- to 3-fold that of adults). The degree of adrenal suppression increases 
with the potency and concentration of the TG, application area, occlusion and 
degree of inflamed skin. Other systemic side-effects include Cushing’s 
syndrome, the aggravation of diabetes mellitus, and increasing or causing 
hypertension and osteonecrosis.
5. Glucocorticoid chemistry
In humans, the naturally occurring corticosteroid is cortisol, or 
hydrocortisone, which is produced primarily in the adrenal gland. The 
majority of TG that are used therapeutically are synthetic derivatives of 
hydrocortisone (Figure 3). Hydrocortisone has an androstane structure 
arranged in four rings, with a relative low potency and a short duration of 
action. The free hydroxyl-group at C-11 is essential for the pharmacological 
effect. Increased glucocorticoid activity (increased affinity for the 
corticosteroid receptor) can be achieved by introduction of an additional 
double bond at C-1 and substitution at the C-16 position. The lipophilicity of 
the steroid and the duration of action are greatly increased by fluorination of 
the B ring at the C-9 and/or C-6 position. Moreover the lipophilicity and 
metabolic resistance of TG may also be increased by adding ester or acetal 
groups to the D-ring (e.g. betamethasone 17-valerate). Clobetasol propionate 
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Figure 3: Structure of hydrocortisone and selected TG of greater potency.
Strategies to optimise the potency and, in particular, the anti­
inflammatory and immunosuppressive capacity of TG, while minimizing their 
adverse effects have been pursued. But ‘ideal’ TG have not yet been 
synthesized. Prednicarbate, hydrocortisone aceponate, mometasone furoate 
and methylprednisolone aceponate are the first, so-called soft-steroids. 
These are 17,21-double esters of hydrocortisone with significant anti­
inflammatory activity, but with the least capacity to induce skin atrophy [53- 
56]. The relative weak side-effects are the result of a specific metabolic step 
and a selective influence on cytokine production.
In vivo, mometasone furoate, methylprednisolone aceponate and 
hydrocortisone induced similar skin atrophy but the soft steroids elicited a 
much greater blanching response [57]. Similarly, prednicarbate caused 
significantly less skin atrophy than the equipotent betamethasone 17-valerate 
[58]. This low atrophogenic effect is the result of its minor effects on IL-1 a 
and IL-6 suppression in dermal fibroblasts; the high degree of IL-1 a
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suppression in epidermal keratinocytes, on the other hand, is almost 
equivalent to that of betamethasone 17-valerate [39,59,60]. Prednicarbate 
(PC) penetrates the epidermis more readily due to esterification at position 
17 and 21. Reaching the keratinocytes, PC is rapidly metabolised to 
prednisolone 17-ethylcarbonate (PEC), which is believed to be primarily 
responsible for anti-inflammatory effect due to its higher receptor affinity. In 
fibroblasts, PEC inhibits IL-1 a and IL-6 much more than PC. However, the 
metabolism of PC in fibroblasts is only 1 % per hour, possibly due to low 
esterase activity. Moreover, the permeation of PC through the epidermis into 
the dermis is very slow, resulting in a negligible atrophogenic effect [60,61]. 
Therefore, these compounds can be used to treat sensitive areas, such as 
the face, and large surface areas in children, with minimal local and systemic 
side-effects [54]. Fluticasone propionate (Figure 4), a fluoromethyl 
androstane-17p-carbiothioate, is another new soft steroid with good anti­
inflammatory activity but a much lower potential to cause systemic side- 
effects. The two esterifications at positions 17 and 20 increase the molecule’s 
lipophilicity, and its uptake by and affinity for the glucocorticoid receptor. The 
small amount of drug that is systemically absorbed is rapidly metabolised to 
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The efficacy of a TG is related to its pharmacological potency and to 
its ability to be absorbed into the target cells within the viable epidermis and 
dermis [63]. Potency is a complex function of the physical and chemical 
properties of both the drug and its vehicle [42,64]. For the TG, a ranking of 
drugs and vehicles has been evolved using the skin blanching assay.
Table 1: Classification of TG according to potency by the National Psoriasis 
Foundation (from www.psoriasis.org).
TG PRODUCT INCORPORATED TG
CLASS I -  Superpotent
Clobex Lotion, 0.05% Clobetasol propionate
Cormax Cream/Solution, 0.05% Clobetasol propionate
Diprolene Gel/Ointment, 0.05% Betamethasone dipropionate
Olux Foam, 0.05% Clobetasol propionate
Psorcon Ointment, 0.05% Diflorasone diacetate
Temovate Cream/Ointment/Solution, 0.05% Clobetasol propionate
Ultravate Cream/Ointment, 0.05% Halobetasol propionate
CLASS II -  Potent
Cyclocort Ointment, 0.1% Amcinonide
Diprolene Cream AF, 0.05% Betamethasone dipropionate
Diprosone Ointment, 0.05% Betamethasone dipropionate
Elocon Ointment, 0.1% Mometasone furoate
Florone Ointment, 0.05% Diflorasone diacetate
Halog Ointment/Cream, 0.1% Halcinonide
Lidex Cream/Gel/Ointment, 0.05% Fluocinonide
Maxiflor Ointment, 0.05% Diflorasone diacetate
Maxivate Ointment, 0.05% Betamethasone dipropionate
Psorcon Cream 0.05% Diflorasone diacetate
Topicort Cream/Ointment, 0.25% Desoximetasone
Topicort Gel, 0.05% Desoximetasone
CLASS III -  Upper Mid-Strength
Aristocort A Ointment, 0.1% Triamcinolone acetonide
Cutivate Ointment, 0.005% Fluticasone propionate
Cyclocort Cream/Lotion, 0.1% Amcinonide
Diprosone Cream, 0.05% Betamethasone dipropionate
Florone Cream, 0.05% Diflorasone diacetate
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Lidex-E Cream, 0.05% Fluocinonide
Luxiq Foam, 0.12% Betamethasone valevate
Maxiflor Cream, 0.05% Diflorasone diacetate
Maxivate Cream/Lotion, 0.05% Betamethasone dipropionate
Topicort Cream, 0.05% Desoximetasone
Valisone Ointment, 0.1% Betamethasone valerate
CLASS IV - Mid-Strength
Aristocort Cream, 0.1% Triamcinolone acetonide
Cordran Ointment, 0.05% Flurandrenolide
Derma-Smoothe/FS Oil, 0.01% Fluocinolone acetonide
Elocon Cream, 0.1% Mometasone furoate
Kenalog Cream/Ointment/Spray, 0.1% Triamcinolone acetonide
Synalar Ointment, 0.025% Fluocinolone acetonide
Uticort Gel, 0.025% Betamethasone benzoate
Westcort Ointment, 0.2% Hydrocortisone valerate
CLASS V - Lower Mid-Strength
Cordran Cream/Lotion/Tape, 0.05% Flurandrenolide
Cutivate Cream, 0.05% Fluticasone propionate
DermAtop Cream, 0.1% Prednicarbate
DesOwen Ointment, 0.05% Desonide
Diprosone Lotion, 0.05% Betamethasone dipropionate
Kenalog Lotion, 0.1% Triamcinolone acetonide
Locoid Cream, 0.1% Hydrocortisone butyrate
Pandel Cream 0.1% Hydrocortisone probutate
Synalar Cream, 0.025% Fluocinolone acetonide
Uticort Cream/Lotion, 0.025% Betamethasone benzoate
Valisone Cream/Ointment, 0.1% Betamethasone valerate
Westcort Cream, 0.2% Hydrocortisone valevate
CLASS VI -  Mild
Aclovate Cream/Ointment, 0.05% Alclometasone dipropionate
DesOwen Cream, 0.05% Desonide
Synalar Cream/Solution, 0.01% Fluocinolone acetonide
Tridesilon Cream, 0.05% Desonide
Valisone Lotion, 0.1% Betamethasone valerate
CLASS VII - Least Potent
Topicals with hydrocortisone, dexamethasone, methylprednisolone and prednisolone
20
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The American classification includes seven potency groups (Table 1)
[65], while the British National Formulary recommends only four (Table 2)
[66]. In the former system, the potency of a product is characterized by the 
corticosteroid, its concentration and the nature of the vehicle. Corticosteroid 
formulations in the same potency group have similar efficacy and a similar 
potential to provoke side-effects. That is, the greater the potency, the greater 
the therapeutic efficacy, but also the greater the adverse effects. Low- 
potency formulations are considered acceptable for long-term treatments 
while the more potent products should be reserved for shorter regimes and 
for use at sites, such as the palms and soles, where low potency 
corticosteroids are ineffective [67]. The British classification system is made 
irrespective of the topical vehicle used.
Table 2: Classification of TG by potency according to the British National 
Formulary (BNF).







0.75 Fluocortyn butyl ester
0.5 Prednisolone
Moderate 0.05 Clobetasone butyrate
0.02 Triamcinolone acetonide
0.005 Fluocinolone acetonide










The dependence of the pharmacological response on the drug 
concentration in the vehicle is classically illustrated by a ‘dose-response’ 
curve (Figure 5) [68], The profile is characterized by (i) a threshold 
concentration S, which is the minimum necessary to induce a response, (ii) a 
range over which the response increases linearly with the logarithm of the 
‘dose’, (iii) the EC50, the concentration that elicits 50 % of the maximal effect, 
and (iv) a plateau (Emax), where further increases in concentration provoke no 
additional pharmacological response. Clearly, different formulations of the 
same steroid can shift the position of the ‘dose-response’ curve by either 
enhancing or retarding the drug’s penetration into the skin. The bioavailability 






vehicle 1 vehicle 2
S 1 S 2 log concentration
Figure 5: Typical ‘dose-response’ curves of two vehicles.
In the early 1970s, Katz and Poulsen described the significance of 
both release (diffusion out of the vehicle) and penetration (diffusion into the 
skin barrier) for topical product design based on corticosteroids [69]. These 
two processes are dependent upon the physicochemical properties of both 
the drug and the vehicle [70].
The skin blanching response of betamethasone 17-benzoate 
increased proportionally with the concentration of the dissolved and diffusible 
drug, reaching the maximal response when the concentration equals the 
solubility of the drug in the vehicle (Figures 6 and 7) [71,72], The blanching
22
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response from suspensions of the drug was independent of the 
betamethasone 17-benzoate concentration [72]. In Figure 6 and 7, the 
blanching response of the test formulations (BT) was related to the maximum 
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Figure 6: Dose response relationship of betamethasone 17-benzoate in 
neutral oil/paraffin 60/40. Means ± SD (n = 17-18). Applied concentrations: 3, 





^ V ~ ^ s ,V (40 /60 )
100 10001 10
concentration [mg/100g]
Figure 7: Dose response relationship of betamethasone 17-benzoate in 
neutral oil/paraffin 40/60. Means ± SD (n = 17-18). Applied concentrations: 1, 
3, 8, 15, 27, 40, 60, 100 and 150 mg/100g (adapted from [72]).
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The amount of drug needed for the same blanching response differs 
according to the steroid solubility in the vehicle. However, the same 
thermodynamic activity of the drug in the vehicle leads to the same 
pharmacodynamic response, provided that the formulation does not change 
either the solubility of the drug in the SC, nor its diffusivity across the SC.
7. Vehicles and formulations
TG are formulated in a variety of vehicles, including ointments, 
creams, lotions, gels and, more recently, foams. As mentioned above, the 
vehicle has a great influence on penetration into the SC and consequently on 
the bioavailability and potency of the glucocorticoid [73,74]. Ointment 
formulations are generally more potent than creams containing the same 
drug presumably due to their occlusive effect on the skin which may increase 
SC hydration and enhance drug transport [40,75,76]. Ointments are preferred 
for infiltrated, lichenified lesions, whereas creams are preferred for acute and 
subacute dermatoses. Lotions and gels are suitable for the treatment of scalp 
psoriasis. The novel, thermolabile, low-residue foam formulations, available 
for betamethasone 17-valerate and clobetasol propionate, are safe and 
effective in the treatment of psoriasis affecting scalp and nonscalp regions of 
the body. The foam formulations are associated with better patient 
compliance and improvements in quality of life [77,78].
The activity of a TG formulation can be enhanced by adding a 
chemical penetration enhancer, which may result in an increase of drug 
delivery into the SC.
Various studies, using a vasoconstrictor assay, have shown that huge 
differences existed between generic and original formulations containing the 
same glucocorticoid in the same concentration in different vehicles [42,79]. 
By altering the vehicle, betamethasone dipropionate, at a concentration of 
0.05 %, has been formulated into four different potency groups (Table 1). 
Class I contains a cream (Diprolene® cream 0.05 %), which is a modified 
vehicle high in propylene glycol. Class II includes an ointment (Diprosone® 
ointment 0.05 %). Class III contains another cream (Diprosone® cream 
0.05 %) with less propylene glycol then the class I formulation. Class V
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incorporates betamethasone dipropionate in a lotion (Diprosone® 0.05 % 
lotion).
Kinetic considerations of the penetration process differentiate between 
solution and suspension-type formulations [80,81]- With suspensions the rate 
of penetration should be independent of the vehicle, on the solubility of the 
drug therein, and on the amount of incorporated drug as long as significant 
depletion does not occur over time [80]. However, in the case of solution-type 
formulations, the vehicle has an enormous influence on the rate of 
penetration. High solubility in the vehicle and a low partition coefficient 
between the SC and the vehicle lead to poor penetration of the drug into the 
SC and low bioavailability [69]. Therefore, it is important to know and control, 
where possible, the thermodynamic activity of the drug in the vehicle.
The dilution of commercially available TG formulations is a common 
practice, which causes problems. The expectation of the prescribing 
physician is that dilution reduces the efficacy of the corticosteroid formulation 
and can be adjusted to the needs of the patient. However, the extent to which 
efficacy is reduced is not always proportional to the degree of dilution. For 
example, a fluocinolone acetonide cream (Synalar® cream), when diluted by 
up to 10-fold, resulted in no significant reduction in potency as assessed by 
the vasoconstrictor assay [82]. A betamethasone 17-valerate ointment 
(Betnovate® ointment) was diluted by a factor of 32 with no statistically 
significant difference in the blanching response [83]. These results strongly 
suggest that the drugs in the original formulations were present as 
suspensions and that, even upon substantial dilution, there remained some 
undissolved drug present. In other words the thermodynamic activity stayed 
at its maximum level; it follows that drug delivery into the skin was not 
changed and the pharmacological response was unaltered. Had the drug 
been present in the original vehicle as a solution, dilution would have lowered 
the thermodynamic activity and led to lower permeation and a lesser 
response. Care must also be taken when diluting formulations with a base, 
which is not the same as the original vehicle. For example, Refai et al. 
showed that the in vitro permeation of hydrocortisone acetate is about 5 
times lower after 1:2 dilution of Soventol® cream with a non-identical base
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(Figure 8) [84]. Soventol® cream contains isopropyl alcohol and the 
penetration enhancer, isopropyl myristate. The reduced delivery is smaller 
than expected probably due to the reduced concentration of the enhancer in 
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Figure 8: In vitro SC permeation of hydrocortisone from 1 % Soventol® cream 
(■), and Soventol® cream diluted with water-containing hydrophilic ointment 
1:2 (•). Amount of drug permeating per unit area (Q/A) was plotted versus 
time (adapted from [84]).
Finally, it should be emphasized that the foregoing discussion is 
applicable specifically to intact, healthy skin, where penetration into and 
through the SC is the rate-limiting step. In the case of damaged skin, the 
release of drug from the formulation will determine uptake, and will be 
controlled by the characteristics of the vehicle.
8. Bioavailability/Bioequivalence testing
Bioavailability (BA) is defined as the “rate and extent to which the drug 
is absorbed from the formulation and becomes available at the site of action” 
(as stated in 21 CFR 320.1 [85]). Bioequivalence (BE) is defined as “the 
absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical 
alternatives become available at the site of drug action when administered at
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the same molar dose under similar conditions in an appropriately designed 
study” (as defined in 21 CFR 320.24 [85]). As mentioned above, for TG the 
sites of action are the glucocorticoid receptors in the viable epidermis and 
dermis. Typical bioavailabilities are only a few percent of the applied dose. 
Several in vivo and in vitro methods have been employed to assess the 
BA/BE of TG, and are summarised in Figure 9.
In Vitro I
Release Studies
Permeation Studies Tape Stripping
Microdialysis
In Vivo
Clinical Trials Vasoconstrictor Assay
M ethods for BA/BE Testing of TG
Figure 9: Methods for BA/BE testing of TG, italicised legends signify those 
methods, which are still under evaluation
For the moment, the only acceptable methods to assess BA/BE of 
topically applied drug formulations are clinical trials between generic and 
original products and pharmacodynamic response studies. Comparative 
clinical trials are considered to be the ‘gold standard’, but these studies are 
relatively insensitive, costly, time-consuming and require large numbers of 
subjects [86]. In contrast, pharmacodynamic response studies are relatively 
easy to perform, expose the subjects to only a small amount of the 
formulation for a short period of time, are fairly reproducible, and require a 
relatively small number of subjects [87]. The TG pharmacodynamic response 
is the ability to produce vasoconstriction of the microvasculature of the skin, 
leading to skin blanching (whitening) at the site of application. This 
“vasoconstrictor assay” was first described by McKenzie and Stoughton in 
1962 [88,89]. Since that time, the method has been modified and extended to 
provide a reliable means to test TG and their formulations. The intensity of
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skin blanching has been correlated with drug potency and the degree of drug 
delivery through the SC [90]. The blanching intensity has also been shown to 
correlate directly to clinical efficacy in patients with plaque psoriasis 
[40,75,91]. The vasoconstrictor assay has been used to measure the BA/BE 
of corticosteroid formulations in healthy volunteers [42,92,93] and has been 
adopted in 1995 for BE determination by the U.S. Food and Drug 
Administration (FDA), in a Guidance document ‘Topical Dermatologic 
Corticosteroids: In Vivo Bioequivalence” [87]. This Guidance counsels both 
pilot and pivotal studies. The preliminary, pilot study is performed to establish 
the dose duration-pharmacological response relationship of a reference listed 
drug (RLD). The formulation is applied for various times (dose durations) up 
to 6 hours to manipulate the amount of steroid delivered. At the end of the 
treatment period, the skin blanching response is measured with a 
chromameter over the next 24 - 28 hours. From the resulting response 
versus time profiles, the areas above the response curves (AARC) are 
calculated and plotted as a function of dose duration to obtain 
dose/response-like relationships (in accordance to Figure 5). From these 
profiles, the maximum AARC (= Emax) and the appropriate dose durations 
ED50, Di and D2 for use in the pivotal bioequivalence study are determined. 
ED50 is the dose duration required to achieve 50 % of Emax, Di and D2 
correspond to one-half ED50 and two times ED50, respectively. The pivotal 
bioequivalence study then compares the in vivo response of the test product 
with that of the RLD using appropriate statistical tools to document whether 
bioequivalence has, or has not, been achieved.
There remains a concern, however, that the design and analysis of the 
pilot study can influence the findings from the pivotal test [94,95], the role of 
the pilot investigation is therefore crucial. A critical factor, which is not 
specified in the Guidance, is the volume of formulation to be applied in vivo. It 
has been reasonably argued that the applied vehicle volume should be the 
same at all sites to ensure accurate and meaningful bioavailability data [95]. 
The situation becomes complex for preparations in which the drug is in 




The chromameter has been adopted by regulatory agencies, such as 
the U.S. FDA, as the current standard for the measurement of corticosteroid- 
induced skin blanching. The chromameter quantifies the reflectance of a 
xenon source light pulse in terms of three measures: the L-scale (light-dark), 
the a-scale (red-green) and the b-scale (yellow-blue). These three values can 
be used to define a point in three-dimensional space that characterizes a 
colour in absolute terms. The Guidance protocol suggests the use of only the 
a-scale values in quantifying the blanching response. The chromameter is 
viewed as an ‘objective’ measurement device compared to ‘subjective’ visual 
scoring. There are several reports comparing the chromameter with the 
visual technique [90,97-99], with other reflectance instruments [100], with 
laser Doppler velocimetry or, more recently, with digital image analysis 
[101,102]. Although, the chromameter has been adopted by the FDA as the 
current standard method for topical BE testing, it has been criticized for 
different reasons [94,97,103] and there are continuing efforts to examine 
alternative approaches. Nevertheless, despite its limitations, the 
vasoconstrictor assay remains the standard procedure to assess the BA/BE 
ofTG.
Other pharmacodynamic effects that may be quantified are the 
vasodilatation (erythema) and skin temperature increase induced by nicotinic 
acid esters [104-108], and the response to local anaesthetic bases [109]. The 
reduction of methyl nicotinate-induced erythema by topical ibuprofen has also 
been correlated with the drug’s concentration in the epidermis [110]. Topical 
retinoids have been shown to increase transepidermal water loss in a time 
and dose-dependent fashion [111,112]; however, the use of this effect for BE 
determination has not been confirmed nor recommended [113].
In summary, therefore, apart from the vasoconstrictor assay, which is 
clearly restricted, at this time, to TG, there are currently no non-invasive or 
minimally invasive techniques for the assessment of BA/BE of topically 
applied drugs that are acceptable to the regulatory bodies. For all other 
topically applied drugs, comparative clinical trials are the only approved 
means with which to establish BE. In an effort to address this situation and to 
provide viable alternatives for BE determination, significant efforts are being
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directed to the dermatopharmacokinetic (DPK) approach, microdialysis and 
the use of in vitro experiments [114].
The DPK method uses tape-stripping to measure drug concentrations 
in the SC. The SC is collected by successive application and removal of 




Figure 10: Schematic representation of the tape-stripping technique.
In theory, the DPK approach may be applied to all topical drugs. The 
principal assumption is that the amount of drug recovered from the SC, the 
usual barrier to percutaneous absorption, is directly correlated with the 
amount reaching the target cells. A recently published comparison of DPK 
and skin blanching response following topical application of triamcinolone 
acetonide and betamethasone dipropionate has validated this hypothesis 
[40,115]. The DPK concept, which evolved from a series of earlier studies 
reported by Rougier et al. [116], was introduced in a Draft Guidance from the 
FDA in 1998 [117]. Over the following 4 years, a number of concerns were 
raised with respect to the relevance of the approach to diseased skin, to the 
applicability of the method to drugs which have rather specific sites of action 
(for example, the hair follicle), and to the reproducibility and practicability of 
the technique. In 2002, a comparative study using tretinoin gels was 
performed in two laboratories and produced conflicting results [118-120]. This 
led, in turn, to withdrawal of the Draft Guidance. Subsequently, the FDA has 
been critically re-evaluating DPK, with a view to improving sensitivity, to 
reducing complexity, and to validating the approach sequentially for specific
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drug classes. Other laboratories have also been contributing to this process 
and the value of improved DPK procedures has been demonstrated for the 
assessment of the BA of drugs whose site of action is the SC itself, such as: 
antifungal drugs [121-124], keratolytics [125-127], UVA/UVB filters [128-131], 
and antiseptics [132].
In principle, microdialysis allows continuous monitoring of the rate and 
extent of drug penetration into the skin. Via a probe (comprising a dialysis 
membrane) inserted into the dermis (Figure 11), the in vivo sampling of 
endogenous and exogenous substances in the extracellular fluid is possible. 
The technique can directly measure, therefore, drug levels within the skin 
and comes closest, as a result, to offering information about BA in the target 
tissue. Further, the method may be used when the skin’s barrier is disrupted 
and has been shown to be applicable to measurements on diseased skin 
[133,134]. Typically, the microdialysis probe (~ 200 pm diameter) is situated 
1-3 mm beneath the skin surface and is perfused with a physiological 
solution (perfusate) at a volume flow rate of -  5 pl/min. The molecular weight 
cut-off of the dialysis membrane is on the order of 20 kDa. The exchange of 
substances across the dialysis membrane occurs by passive diffusion and 
depends on the relevant concentration gradient. These attractive features 
must be balanced against a number of significant challenges. First, and 
foremost, the technique is invasive and is difficult to perform; although very 
little biological fluid is removed, the mere insertion of the microdialysis probe 
can cause transient inflammation and the local release of various biological 
factors (e.g., cytokines) [135-137]. Second, the duration of a microdialysis 
experiment is necessarily limited for practical reasons, and this creates a 
problem for slowly or poorly permeating substances. Relatedly, recoveries 
are typically low: that is, the concentration of analytes in the perfusate is so 
low that analysis becomes difficult; this is particularly true for lipophilic drugs, 
such as betamethasone 17-valerate, or drugs which are highly protein- 
bound, which do not distribute significantly into the aqueous perfusate in the 
microdialysis probe [138,139]. Finally, to relate the amount of analyte in the 
perfusate to its real concentration in the skin, it is necessary to use a so 
called “retrodialysis marker” (of similar physicochemical properties) to
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calibrate the recovery efficiency [140-142]. Overall, while microdialysis is an 
alternative option, the outstanding challenges preclude, at the present time, 










% • V #. v  • •f  • • y »  •
Diffusion of drug into the perfusate
• • Dialysate
• = drug
Figure 11: Schematic representation of the principle of the microdialysis. The 
probe is inserted in the dermis and is perfused at a flow rate controlled by the 
pump. Drug from the applied formulation permeates the SC and viable 
epidermis and eventually diffuses passively into the lumen of the membrane. 
The dialysate is sampled at fixed time intervals.
Finally, it is appropriate to describe briefly the value of in vitro 
procedures in the BA/BE evaluation of topical drug products. While the 
SUPAC-SS (“release test”) procedure [143] is valuable as a tool for quality 
control, it is not appropriate for BE assessment except for very minor 
formulation changes. On the other hand, it may be said that in vitro skin 
permeation experiments have proven to be valuable guides in formulation 
development. Flowever, the regulatory agencies (especially the FDA) have 
been reluctant to adopt such an approach for BA/BE determination. While 
there are reasonable concerns about the provision of human skin, of 
sufficient quality and quantity, for routine use, there are probably situations, 
particularly for drugs of balanced lipophilicity/hydrophilicity, in which an in 
vitro skin penetration comparison of formulations would be perfectly 




TG are an integral part of dermatological therapy. Despite years of 
use, however, the topical BA of these drugs remains difficult to assess and 
has rarely been properly optimised. While it is generally agreed that their BA 
is poor, a quantitative measure of this key parameter has proven elusive. In 
vitro experiments do provide flux and permeability values but, from a 
regulatory standpoint, this information is viewed as complementary rather 
than definitive and clinical triais are the ‘gold standard’ with which to assess 
efficacy. BE may, in the right circumstances, be determined using the 
vasoconstrictor assay, and the use of the chromameter to assess objectively 
skin blanching is an improvement in the application of this method. However, 
this determination of a pharmacological response remains some way from an 
absolute measurement of the amount of drug in the skin (at or near the target 
site) and the rate at which it arrived there. Consequently, much effort is 
presently focused on different approaches to estimate BA and BE of TG and 
other dermatological drugs. The dermatopharmacokinetic (tape-stripping) 
and microdialysis techniques are the most seriously considered at this time. 
Both have clear advantages and drawbacks, and it remains to be seen which 
one (if any) will emerge as a viable methodology to move forward and 
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Abstract
Objective: To compare the in vivo bioavailability profiles of two formulations 
of betamethasone 17-valerate (BMV) assessed using the 
dermatopharmacokinetic (DPK) approach and the vasoconstrictor assay. 
Methods: BMV was formulated either in a medium chain triglyceride gel 
(MCT) or in a brand microemulsion (ME), at 80 % of its saturation level. Drug 
uptake into and elimination from the stratum corneum (SC) were assessed by 
the DPK approach using tape-stripping. The skin blanching response was 
quantified during 24 hours after a 2 and 6 hour drug application.
Results: With the vasoconstrictor assay, no difference in the blanching 
response between the two formulations was observed; however, there was a 
statistical difference in the amount of BMV taken up into the SC between the 
two formulations as measured by the DPK approach. BMV delivery into the 
SC was 5-fold higher from the ME than that from the MCT formulation. 
Conclusion: The results of the vasoconstrictor assay suggest that the 
blanching response had been saturated, preventing any differences between 
the two formulations to be observed. In contrast, the DPK method, which was
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The efficiency of topical delivery is notoriously inefficient, with typical 
bioavailabilities of only a few percent of the applied dose. Rational 
development of better formulations requires better creativity and better 
methods with which to quantify bioavailability (BA) and bioequivalence (BE) 
of drug delivery to a target in the skin. Topical BA/BE evaluation typically 
requires clinical trials, which are invasive, relatively insensitive, time- 
consuming and costiy. In the case of topical glucocorticoids (TG), however, 
BA/BE can be assessed using the vasoconstrictor assay. This non-invasive 
method relies on the pharmacodynamic response of TG in the upper layers 
of the skin that causes visual and quantifiable blanching due to 
vasoconstriction and, in 1995, the U.S. Food and Drug Administration (FDA) 
published a Guidance document for TG BE testing [1]. This Guidance 
consists of two distinct in vivo components: a pilot study and a pivotal test. 
The pilot study is carried out to explore the dose duration-response 
relationship of a reference listed drug (RLD) and to determine the appropriate 
dose duration for use in the pivotal test. The pivotal test then compares the in 
vivo response of the test product with that of the RLD to document whether 
BE has, or has not, been found.
Apart from TG, for all other topical drugs, however, the vasoconstrictor 
assay is not useful to document BA/BE and at the moment, clinical trials are 
the only option. In 1998, the FDA proposed an alternative, potentially more 
generally applicable, technique instead: the dermatopharmacokinetic 
approach (DPK), analogous to the pharmacokinetic method of oral drug 
BA/BE assessment [2,3]. The DPK approach, using tape-stripping, evaluates 
topically applied drug levels in the outermost layer of the skin, the stratum 
corneum (SC), as a function of time post-application and post-removal of the 
formulation. The Draft Guidance [2] allows the assessment of both drug 
uptake into and drug elimination from the SC. At specific times, layers of the 
SC are sequentially removed at the treated site with adhesive tapes and the 
total amount of drug is subsequently analysed therein. From the DPK profile 
of drug mass in the SC as a function of time, pharmacokinetic parameters 
such as the area under the curve (AUC), the maximum amount drug in the
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tape-strips ( A max) and the time ( T max) at which A max is observed are deduced 
and used to characterize the local B A .
It is assumed that SC drug levels are directly related to those in the 
epidermis and/or dermis, as the SC is typically the rate-determining barrier to 
percutaneous absorption. In other words, it is hypothesized that the rate and 
extent of drug disposition in the SC will reflect that achieved at target sites 
which are further into the skin. While the DPK Guidance has been withdrawn, 
and the details of the methodology are being reconsidered, there have been 
experiments using commercially available TG products in which the drug 
uptake phase into the SC using tape-stripping have been favourably 
compared with the pharmacodynamic response [4-7]. On the other hand, 
there has been criticism made of the DPK procedure used in these earlier 
experiments, especially with regard to the need for better quantification and 
control of the amount of SC removed and subsequently extracted, and 
certain modifications in the procedure have been recommended. However, 
apart from studies with tretinoin [8-10], there have been no DPK experiments 
with TG, investigating both the uptake and elimination phases.
The goal of this work, therefore, was to compare the topical BA 
profiles of two formulations of betamethasone 17-valerate obtained using the 
methods of the vasoconstrictor assay and of the DPK approach as specified 
in the Draft Guidance [2]. Drug concentrations in the vehicles compared were 
adjusted to the same thermodynamic activity. Pharmacokinetic (model- 
based) parameters of drug disposition in the SC, together with the ‘classic’ 
metrics of (i) the area under the curve, (ii) the magnitude of the maximum 
delivery/response, and (iii) the time required to reach this maximum, were 
determined and used to characterize local BA. Given the typical dosing 
regimen of the drug, the longest treatment time to characterize the uptake 
phase in the SC was chosen to be 6 hours. For the vasoconstrictor assay, an 
additional dose duration of 2 hours was investigated. The ‘reference’ 
formulation comprised medium chain triglycerides, which were not expected 
to exert specific vehicle effects [11]. The ‘test’ vehicle was a commercial 
microemulsion that might be expected to increase drug delivery to the skin.
54
Chapter 2
2. Materials and methods
2.1. Preparation of the formulations
Betamethasone 17-valerate (BMV) (Crystal Pharma, Boecillo, Spain) 
was dissolved in the reference vehicle consisting of medium chain 
triglycerides (MCT) (Mygliol 812 N, Synopharm, Barsbuttel, Germany) and in 
the test microemulsion Mikro 100® (ME) (Sebapharma, Boppard, Germany). 
The components of the ME were aqua, polysorbate 20, polyglyceryl-6 
dioleate, ethylhexyl cocoate, PEG-8 caprylic/capric glycerides, alcohol 
denat., tocopheryl acetate, ectoin, panthenol, centella asiatica, ethoxydiglycol 
oleate, sodium lactate, parfum and phenoxyethanol. The BMV concentration 
was adjusted to 80 % of the saturation level (Table 1) to ensure equivalent 
thermodynamic activity. The saturation levels of BMV in MCT and ME were 
determined by stirring a suspension of drug substance in the vehicles at 32 
°C until equilibrium was attained (about 72 hours). The samples were 
centrifuged, appropriately diluted and analysed by HPLC (see method 
below). The experiments were performed in triplicate. To avoid spreading of 
the formulations on the skin, MCT and ME were gelled, with 15 % (w/w) 
polypropylene and 10 % (w/w) Aerosil® 200 (Sigma-Aldrich, Steinheim, 
Germany), respectively.
Table 1: Saturation levels of BMV at 32 °C in two vehicles. Mean ± SD, n = 3.
Vehicle Saturation level [mg/ml]
MCT 2.1 ±0 .2
ME 11.7 ±0.4
2.2. DPK study
The DPK study was carried out according to the FDA Draft Guidance
[2]. Six human volunteers (females, aged 25 - 32 years) participated in the 
study, which was approved by the Commission d’Ethique, Departement des 
Neurosciences cliniques et Dermatologie, Hopitaux Universitaires de 
Geneve. All subjects were in good general health and had no history of 
dermatological disease. The same infinite volume (250 pi) of each
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formulation was placed in a 1.2 cm diameter Hill Top Chamber® (Hill Top 
Research Inc., Cincinnati, OH, USA) and affixed via an adhesive tape to the 
volar aspect of the forearm. A maximum of six chambers, three with the MCT 
formulation and three with the ME, were applied to each forearm (Figure 1). 
For drug uptake, the formulations were applied to the left forearm and the SC 
samples were collected from each site immediately after removal of the 
chambers at 2, 4 and 6 hours. To assess drug elimination, the formulations 
were applied to the right forearm, and maintained in place for 6 hours. All 
formulations were then removed (using dry paper swabs) and SC samples 





Figure 1: Application scheme. T = test vehicle (ME), R = reference vehicle 
(MCT). Uptake phase 2 to 6 hours ; elimination phase 8 to 30 hours
SC stripping used Scotch Book Tape (3M, St. Paul, MN, USA). The 
SC sampling site was delimited by a template, which was centred over the 
drug application site. The tape ( 2 x 2  cm) was applied over the template, 
pressed uniformly and removed. Each treated skin site was initially tape- 
stripped 12 times; additional tape-strips were taken, if necessary, until the 
value of transepidermal water loss (TEWL) was 4-fold greater then the pre­
stripping value measured at an adjacent skin site and untreated with either 
formulation. Periodic measurements of TEWL (Evaporimeter EP1,
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Servomed, Stockholm, Sweden), before and after the stripping process, were 
performed. A 4-fold increase in the TEWL value should ensure that at least 
75 % of the SC was removed at each skin site [12]. The first tape-strip was 
discarded to avoid potential residual drug contamination. The drug on the 
remaining tape-strips was subsequently extracted and analysed by HPLC 
(see method below). The total amount of BMV recovered from the tape-strips 
was expressed in micrograms per square centimetre (pg/cm2).
2.3. Extraction and HPLC analysis of BMV
The tapes were extracted, in groups of 5 or fewer, by shaking 
overnight with 2.0 ml of 60:40 (v/v) acetonitrile/water (Sigma-Aldrich, 
Steinheim, Germany). BMV in the extracted samples was then quantified by 
HPLC (Dionex, Sunnyvale, CA, USA) with UV detection at 239 nm using a 
Lichrospher® 100 RP-18 (4 x 125 mm) column (Merck, Darmstadt, Germany). 
The mobile phase consisted of degassed acetonitrile - distilled water - 
triethylamine - phosphoric acid (60:40:0.1:0.05 v/v); the flow rate was 1 
ml/min with a 50-pl sample loop. The retention time of BMV was 3.4 minutes.
2.4. Vasoconstrictor assay
The vasoconstrictor assay was carried out according to the pilot study 
(staggered application with synchronized removal) described in the FDA 
Guidance, “Topical Dermatologic Corticosteroids: In vivo Bioequivalence” [1]. 
Six healthy volunteers (3 male, 3 female, aged 2 1 - 5 5  years) from whom 
informed consent was obtained, participated in the study, which was 
approved by the Ethics Committee of the University of Leipzig. Once again, 
250 pi of each formulation were applied via a 1.2 cm diameter Hill Top 
Chamber® to the ventral forearm. In addition, a drug-free vehicle control was 
applied. Dose durations of 2 and 6 hours were chosen. The skin blanching 
response was assessed with a chromameter (CR-300, Minolta, Ahrensburg, 
Germany) using the a-scale values at 0, 2, 4, 6, 19 and 24 hours after 
formulation removal (Figure 2). The instrument was calibrated using a white 
plate immediately before use. Baseline readings were taken at all sites prior 
to the application of the formulations. The a-scale readings for each drug
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application site were adjusted for the baseline value and the control and 
expressed as the change in this parameter (Aa).
Baseline (BL) measurement, Formulation skin Blanching Measurements T
Application'!' and Removal 'f '
BL ^
f  f  a. xi JJ -t j j x .
I I I--------------------1--------------------1-------------------- 1--------------------1----------------- 1 I I I I I I I I 1 I I 1 I
-7 -6 -5 -4 -3 -2 -1 0 0 2 4 6 8 10 12 14 16 18 20 22 24
Hours Before Formulation Removal ^  Hours After Formulation Removal
Figure 2: Staggered application with synchronized removal: Schematic 
representation of the pilot study protocol [1].
2.5 Pharmacokinetic analysis
For assessment of the BA of BMV delivered from the two formulations, 
the area under the curve (AUC), the maximum amount of BMV in the tape- 
strips (Amax), and the time point at which this maximum was attained (Tmax), 
were determined from the DPK profiles. From the blanching response profiles 
(Aa versus time after formulation removal), the area above the response 
curve (AARC), the maximum blanching response (Aamax), and Tmax were 
estimated. The AUCs and AARCs were calculated using the trapezoidal 
method.
For both the DPK method and for the vasoconstrictor assay (VA), the 
increased BA of the test vehicle (ME) relative to that of the reference (MCT) 
was expressed as an enhancement factor EF according to the following 
equations:
E F dpk=x o ^  E q 1




The DPK profiles of SC levels of BMV as a function of time were 
modelled assuming that the infinite doses applied provided an essentially 
zero-order delivery of drug into the measurement ‘compartment’ from which a 
first-order clearance subsequently occurred:
where k0 and ke were zero-order input and first-order elimination rate 
constants, respectively, and ( B M V ) e/d represents drug which has reached the 
viable epidermis and dermis where the steroid elicits its vasoconstriction 
response [13,14].
The elimination rate constant (ke) may be determined by the decay of 
BMV levels in the SC post-removal of the formulation at 6 hours (A6-3o)'
where A6 is the amount of drug in the SC at 6 hours. With this kinetic 
constant, the zero-order input rate (k0) can then be deduced from the uptake 
portion of the DPK profile:
2.6. Statistics
Paired two-tailed Student’s t-tests were used. P-values < 0.05 were 
considered statistically significant.
( B M V ) surface *  ( B M V ) s c    ( B M V ) e/d







Figure 3 compares the DPK profiles of BMV delivered from MCT and 
ME. Significant differences in the amount of drug in the SC were observed at 
all time points between the two vehicles. ME was clearly the more effective 
formulation. At 6 hours, SC uptake of BMV from the ME was about 6 pg/cm2, 
compared to only 1 pg/cm2 from the MCT formulation. The corresponding BA 
parameters AUC and Amax (Table 2) reflect this observation, and both differ 
significantly between the two vehicles (P < 0.05). The Tmax values for the two 
vehicles were not significantly different, on the other hand. The E F Dpk (Eq. 1) 
was 5.05 ± 1.25, clearly indicating that drug delivery into the SC from the ME 
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Figure 3: DPK profiles (amount of BMV versus time) of reference (MCT ■) 
and test (ME O) formulations. Mean ± SD, n = 6. For the uptake phase, 
formulations were removed at 2, 4 and 6 hours. For the elimination phase, 
formulations were maintained to the skin for 6 hours, subsequently removed, 
and the SC was stripped after a further 2, 6 and 24 hours.
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When the DPK profiles were fitted to Eqs. 3 and 4, no difference in the 
ke values for the two formulations were found; in contrast, the estimated zero- 
order input rate from the ME was significantly higher than that from the MCT 
formulation (Table 2). The vehicle had a clear influence, therefore, on drug 
uptake.
Table 2: Pharmacokinetic parameters (AUC, Amax, Tmax) and rate constants 
calculated from the DPK profiles of BMV applied in MCT and ME. Mean ± 
SD, n = 6.
AUC(2-30) Amax Tmax k0 ke
[pg-h/cm2] [pg/cm2] [h] [pg/cm2/h] [h 1]
MCT 17.6 ±3 .6 1.15 ±0.32 5.7 ±0.8 0.24 ± 0.07 0.04 ± 0.02
ME 86.5 ±15.1* 7.92 ± 1.50* 4.3 ±2.0 1.63 ± 0.23* 0.06 ± 0.02
^Significantly different from the reference vehicle, P < 0.05
3.2. Blanching profiles
The skin blanching response profiles following 2-hour and 6-hour dose 
durations are shown in Figure 4. The derived BA parameters are in Table 3. 
Interestingly, no significant differences between the formulations were 
observed, in contrast to the DPK results. The longer dose duration generally 
resulted in greater initial vasoconstriction, more negative values of Aamax and 
AARC but these differences were not dramatic, and EFVa ~ 1. At all 
experiments, the time at which the maximum response occurred (Tmax) was 6 
hours post-removal of the formulation. This suggests that BMV taken up into 
the SC during the application period was still transporting through the barrier 
to the receptors after the vehicle had been removed from the skin. As the 
DPK experiments clearly show that more BMV is delivered from the ME, 
relative to MCT, the chromameter results appear to imply that the blanching 
response has been saturated and cannot be used, in this case, to distinguish 
the formulations. It is possible that a shorter dose duration might allow some 
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Time after formulation removal [h]
Figure 4: Chromameter (Aa) blanching versus time profiles of MCT (■) and 
ME (O) after different dose durations: 2 hours (A) and 6 hours (B). Time zero 
equals time of formulation removal. Mean ± SD, n = 6.
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Table 3: Pharmacokinetic parameters (AARC, Aamax, Tmax) calculated from 
the blanching profiles of BMV applied in MCT and ME for different dose 
durations. Mean ± SD, n = 6.
Dose duration 
[h]
AARC(0-24) Aamax Tmax [h]
MCT 2 -36.5 ± 8.4 -2.43 ± 0.65 5.3 ±1 .0
6 -47.2 ±10.3 -3.15 ±0.52 6.0 ±0 .0
ME 2 -44.3 ± 9.2 -3.08 ± 0.71 5.7 ±0.8




The DPK results show that the ME formulation obviously enhances 
steroid delivery into the SC. The use of microemulsions to improve topical BA 
has been reported on numerous occasions [15-20], and has been related to 
the ability of these vehicles to improve drug solubilisation in the intercellular 
lipids of the SC [17,18,21]. This mechanism would be consistent with the 
observed EFDpk of about 5 despite the fact that the thermodynamic activities 
of BMV in the ME and MCT formulations were identical.
As alluded to above, the divergent results from the vasoconstrictor 
assay suggest that the blanching response had been saturated even at the 
lower level of drug delivery from the MCT vehicle. Of course, with any 
pharmacodynamic response, this is a potential issue and it is important, 
therefore, to operate in the linear part of the ‘dose-response’ curve whenever 
quantitative conclusions about BA/BE are to be drawn. The saturation of 
steroid blanching response has been described on more than one occasion 
in the literature e.g. [22-24], and it is reasonable to conclude that this has 
again been observed here. Considerable care should be exercised, 
therefore, in using the vasoconstrictor assay as a means to validate the DPK 
approach. Although the DPK approach distinguishes clearly between the two 
formulations, some clear weaknesses in the Draft Guidance have been 
exposed, and the document was withdrawn in 2002. As well as concerns 
about reproducibility of the method between laboratories, there are flaws 
resulting from the attempt to design a procedure which mirrors that used for 
oral BA assessment. For orally delivered drugs, the duration of the uptake 
and clearance phase is controlled by dose, absorption rate, distribution and 
elimination. For topically delivered drugs, according to the DPK study, the 
duration of the uptake phase is controlled by the time at which the remaining 
formulation is removed from the skin surface. As a result Amax and Tmax are 
strongly dependent on the application time. Moreover, unlike the AUC 
determined from drug levels in the blood, the AUC measured in the DPK 
method does not characterise the dose, but instead combines the effect of 
dose and removal time. This means, that the relative contributions of the 
uptake and elimination phase to the AUC can be altered significantly by
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changing the application time before removing the formulation from the skin 
surface [25]. These points are illustrated by the results of this study.
Nevertheless, the DPK methodology employed was reproducible and 
sensitive to differences between the vehicles tested. The procedure involved, 
while not yet optimised, and perhaps more complicated than the 
vasoconstrictor assay, is nevertheless straightforward and relatively easy to 
perform. With modification, therefore, and further development, as already 
described in recent publications [26,27], the DPK approach may offer a more 
quantitative and objective strategy for topical BA/BE assessment of TG than 
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Abstract
Objective: To compare the in vivo bioavailability of different formulations of 
betamethasone 17-valerate (BMV) using the vasoconstrictor assay and the 
dermatopharmacokinetic (DPK) method.
Methods: BMV was formulated in different vehicles and the drug 
concentration was adjusted to (i) equal thermodynamic activity and (ii) a 
range of different concentrations. Skin blanching response was quantified 
after removal of the formulation over 24 hours with a chromameter. Drug 
uptake into the stratum corneum (SC) was assessed by tape-stripping. 
Results: Same thermodynamic activity leads to similar skin blanching 
response of BMV delivered from different vehicles, while the DPK profiles 
distinguish clearly between the formulations. Applying different BMV 
concentrations resulted in a clear concentration dependence of both the skin 
blanching response and the drug uptake into the SC. However, the saturable 
nature of the pharmacodynamic response is obvious.
Conclusion: The vasoconstrictor assay is a well accepted and extensively 
employed method to determine bioavailability/bioequivalence of TG. Its 
results have to be analysed with care due to the saturable nature of the 
pharmacodynamic response. The tape-stripping method, on the other hand, 
showed reasonable reproducibility and distinguished clearly between
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different formulations and different concentrations but more validation work 




Topical glucocorticoids (TG) are widely used in the treatment of 
inflammatory skin diseases, such as psoriasis and atopic dermatitis, due to 
their vasoconstrictive, anti-inflammatory, immunosuppressive and 
antiproliferative effects. The clinical effectiveness depends on their 
bioavailability (BA) within the skin at the site of action. For TG, the site of 
action is within the viable epidermis and dermis, where the glucocorticoid 
receptors are located [1,2].
Generally, BA of TG is very poor. In part, this is due to inefficient 
formulations. As well, the absence of quantitative methods with which to 
assess the rate and extent of drug delivery to the target into the skin is a 
contributory factor. For the moment, the determination of topical BA is 
inferred from a demonstration of safety and efficacy via clinical trials.
For TG, bioequivalence (BE) can be estimated either by comparative 
clinical trials or via application of the vasoconstrictor assay. This latter, non- 
invasive method is based on the ability of TG to cause measurable skin 
blanching. Based on this pharmacodynamic response, the U.S. Food and 
Drug Administration (FDA) published a Guidance document in 1995, entitled 
“Topical Dermatologic Corticosteroids: In vivo Bioequivalence” [3] for BE 
testing of TG. This Guidance consists of pilot and pivotal studies. The former 
is carried out to explore the dose duration-response relationship of a 
reference listed drug (RLD) and to determine the appropriate dose duration 
for use in the pivotal study. The latter then compares the pharmacodynamic 
response of the test product with that of the RLD so as to determine whether 
bioequivalence has, or has not, been achieved.
However, the vasoconstrictor assay is obviously not generally 
applicable to all topical drugs, and alternative procedures for topical BE 
assessment are required which are less expensive, less time-consuming and 
more sensitive than clinical trials. One interesting and increasingly 
investigated method involves tape-stripping the skin’s outermost layer, the 
stratum corneum (SC). In 1998, the FDA released a Draft Guidance 
proposing a dermatopharmacokinetic (DPK) method, using tape-stripping,
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which evaluates topically applied drug levels in the SC as a function of time 
post-application and post-removal of the formulation [4,5]. The SC is 
collected by successive application and removal of adhesive tape and the 
total amount of drug is subsequently analysed therein. The DPK method 
assumes that SC drug levels are directly related to those in the viable 
epidermis and/or dermis, as the SC is typically the rate-determining barrier to 
percutaneous absorption. In 2002, however, this Draft Guidance was 
withdrawn mainly because of doubts regarding reproducibility, flaws resulting 
from the similar design of the approach to oral BE assessment, and criticism 
that quantification of the amount of SC removed should be better controlled.
As a consequence, a critical re-evaluation of the DPK method is in 
progress, with a clear objective being to validate the approach. Important 
progress has been made with respect to quantification and standardization of 
the amount of SC removed during tape-stripping such that drug concentration 
profiles across the membrane can now be expressed on the same scale: that 
is, as a function of the relative position within the SC [6]. Equally, 
dermatopharmacokinetic parameters, characterizing drug partitioning and 
diffusivity into and through the SC, can be deduced and used to quantify, 
respectively, the extent and rate of drug delivery. These advances have been 
illustrated for terbinafine [7-9] and for ibuprofen [10,11] delivered from 
different vehicles.
The goal of this study was to explore the challenge of validating the 
DPK methodology by comparing the assessment of the topical BA of 
betamethasone 17-valerate using the vasoconstrictor assay and the tape- 
stripping approach. The sensitivity of the techniques, and their ability to 
discriminate between different formulations, was examined as a function of 
the applied drug concentration (and its thermodynamic activity).
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2. Materials and methods
2.1. Determination of the saturation level
The saturation level (Cs,v) of betamethasone 17-valerate (BMV) 
(Crystal Pharma, Boecillo, Spain) in each vehicle was determined by stirring 
a suspension of the drug in the formulation at 32 °C until equilibrium was 
attained (about 72 hours). The samples were centrifuged, diluted either with 
acetonitrile alone or with acetonitrile/water 60:40 (v/v) and analysed by liquid 
chromatography (see method below). The saturation level of BMV in light 
mineral oil was determined using the iterative method of visual clouding. The 
experiments were performed in triplicate.
2.2. Preparation of the formulations
BMV was dissolved in (i) the reference vehicle, medium chain 
triglycerides (MCT) (Mygliol 812 N, Synopharm, Barsbuttel, Germany), and in
(ii) light mineral oil (LMO) (Synopharm), (iii) the microemulsion Mikro 100® 
(ME) (Sebapharma, Boppard, Germany), and (iv) Transcutol® P (TCL) 
(Gattefosse, Saint Priest, France), as test vehicles. Either 15 % (w/w) 
polypropylene or 10 % (w/w) Aerosil 200® (Sigma-Aldrich, Steinheim, 
Germany) was used as gelling agent.
In the first part of the study, the BMV concentration was adjusted to 
80 % of the saturation level in each vehicle to provide the drug at equivalent 
thermodynamic activity (Table 1).
Table 1: Saturation level of BMV in different vehicles at 32 °C.
Mean ± SD, n = 3.
Vehicle Saturation level (Cs,v) [mg/ml]
LMO 0.0021 ±0.0003
MCT 2.1 ±0.2




In the second component of the investigation, only the MCT and ME 
vehicles were evaluated and the BMV concentration was adjusted to different 
degrees of its saturation level (Table 2).
Table 2: Thermodynamic activities of BMV, expressed as degree of CSlv. and 
concentrations studied in the second set of experiments using ME and MCT 
formulations only.
Degree of Cs,v 0.80 0.10 0.05 0.026 0.013 0.0064 0.0032
Cy ME [mg/ml] 9.3 1.2 0.6 0.3 0.15 0.07 0.04
Cv MCT [mg/ml] 1.7 0.2 0.027 0.013
MCT was chosen as the reference vehicle as it was not expected to 
have any effect on skin barrier function per se [12]. BMV was selected as a 
typical, and frequently used, class 2 TG [13]. BMV has a relatively high 
molecular weight (476.6 Da) and is quite lipophilic (log(octanol/water partition 
coefficient) = 3.78).
2.3. Vasoconstrictor assay
Twelve healthy volunteers, aged 21 - 55 years, from whom informed 
consent was obtained, participated in the study, which was approved by the 
Ethics Committee of the University of Leipzig. The study followed the 
“staggered application with synchronized removal” method of the FDA 
Guidance “Topical Dermatologic Glucocorticoids -  In vivo Bioequivalence”
[3]. 250 pi of each formulation were applied in a 1.2 cm diameter Hill Top 
Chamber® (Hill Top Research, Cincinnati, OH, USA) which was affixed with 
adhesive tape. The drug application sites were on the volar forearm, at least 
4 cm from the wrist and 4 cm from the antecubital fossa. The amounts of the 
formulations applied ensured infinite dose conditions.
In the first part of the study, LMO, ME and TCL were compared with 
the reference vehicle, MCT. The formulations, as well the drug-free vehicles 
as control, were applied to the skin for dose durations of 2, 3, 4, 5 and 6 
hours. The chambers were then removed and excess formulation was 
cleaned off with a dry paper towel. The skin blanching response was
78
Chapter 3
assessed with a chromameter (CR-300, Minolta, Ahrensburg, Germany) 
using the a-scale values at various times up to 24 hours following formulation 
removal. The chromameter was calibrated using an optically white plate 
immediately before use. Baseline readings were taken at all sites prior to the 
application of the formulations. The a-scale readings for each drug 
application site were adjusted for the baseline value and the control and 
expressed as the change in this parameter (Aa). As the a-scale values 
decrease with increasing skin blanching, Aa is negative. The degree of 
response was therefore expressed as the (positive) area above the response 
curve (AARC) using the trapezoidal rule.
In the second series of experiments, BMV, at different degrees of 
saturation in MCT and ME, were applied to the forearm for 4 hours (Table 2). 
After removal of the formulations, the skin blanching response was assessed 
as before over the 24 hour period after formulation removal.
2.4. Tape-stripping
Six healthy Caucasian volunteers (4 female, 2 male, 23 - 41 years) 
with no history of dermatological disease participated in these 
measurements, which were approved by the Salisbury Research Ethics 
Committee. Written consent was obtained from all subjects.
A single infinite dose volume of 600 pi of each BMV formulation, was 
applied using a 1.8 cm diameter Hill Top Chamber® on the volar aspect of the 
forearm, no closer than 4 cm from the bend of the elbow and from the wrist. 
After a 2-hour application (dose duration), the chambers were removed and 
excess formulation was cleaned off with a dry paper towel. Immediately after 
cleaning, the SC at the treated site was progressively removed by repeated 
adhesive tape-stripping (Scotch Book Tape, 3M, St. Paul, MN, USA). A piece 
of polypropylene foil with a predefined hole was placed onto the cleaned, 
treated skin site and affixed with self-adhesive tape. This template ensured 
that all tape-stripping procedures took place at the same site. The tape (2.5 x
2.5 cm) was applied over this template, using a constant pressure (140 
g/cm2) via a weighted roller and then removed. Up to 20 strips were taken 
from each site, but the SC was never completely removed. To ascertain the
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remaining skin barrier function, transepidermal water loss (TEWL) 
measurements were performed (AquaFlux V4.7, Biox Systems Ltd., London, 
UK) during the stripping procedure, which was stopped when TEWL reached 
60 g/m2h. Each tape was carefully weighed before and after stripping on a 
10-pg precision balance (Mettler AT 261, Greifensee, Switzerland) to 
determine the mass and thickness of the SC layer removed [14]. BMV in the 
tape-strips was subsequently extracted quantitatively and analysed by liquid 
chromatography (see method below). The amount of BMV on each strip was 
then converted to a concentration corresponding to a specific depth into the 
SC.
To calculate the total thickness of the SC, the same tape-stripping 
procedure was performed at an adjacent, untreated skin area with 
measurements of TEWL after each tape-strip [14]. The amount of SC 
removed on each tape was again determined gravimetrically. From this 
mass, the known stripped area, and the density of the tissue (about 1g/cm3
[15]), it was possible to calculate the total thickness of the SC from the x- 
intercept of a graph of 1/TEWL versus the cumulative thickness of SC 
removed [14]. Knowing the SC thickness of each subject made it possible to 
express all BMV concentration profiles as a common function of the relative 
position (depth) into the SC, greatly facilitating objective comparison [6,16].
2.5. Extraction and HPLC analysis of BMV
Each tape was completely extracted by overnight shaking with 1.0 ml 
of 60:40 v/v acetonitrile:water (Sigma-Aldrich, Steinheim, Germany). 
Validation of the extraction procedure involved spiking tape-stripped samples 
of untreated SC with a known quantity of BMV. Recovery was 96.9 ± 3.4 % 
(n = 5). BMV in the various samples was quantified by high-performance 
liquid chromatography (HPLC) analysis (Dionex, Munich, Germany) using a 
Lichrospher® 100 RP-18 (4 x 125 mm) column (Hichrom, Reading, UK) with 
UV detection at 240 nm. The mobile phase was degassed 
acetonitrile:deionised water (60:40 v/v) and was delivered at a flow rate of 
1 ml/min in a 50-pl sample loop. The retention time of BMV at 25 °C was
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~ 3.8 minutes. A calibration curve was generated with the pure compound at 
5 different concentrations. The detection limit was 0.03 pg/ml.
2.6. Analysis of the concentration profile data
The SC distribution profiles of BMV (i.e. drug concentration (Cx) as a 
function of position (x) within the SC and time (t)) were fitted to the 
appropriate solution of Fick’s second law of diffusion [17]:
Cx -  KCV
D1 -  — -  — Z  -  sin(n7u—) exp(— n27t2t)
K n=1 n
Eq. 1
where Cv is the BMV concentration in the vehicle, K is the apparent partition 
coefficient of BMV between the SC and the applied vehicle, and D is the 
diffusivity of the drug in the SC of total thickness L.
The analysis assumes the following boundary conditions: (i) at the skin 
surface (x = 0), for the entire duration of the experiment, the BMV 
concentration is K C V; (ii) at t = 0, the SC contains no drug; and (iii) at the 
inner surface of the SC (x = L), perfect ‘sink’ conditions exist for the drug.
Fitting the experimental data to Eq. 1 (using GraphPad Prism® 4.03 
software, San Diego, CA, USA) allowed estimates of K and D/L2 to be 
derived. The latter has units of a first-order rate constant (time'1), and is a 
‘classic’ diffusion parameter derived from these experiments [18]. Integration 
of Eq. 1 yields the area under the drug concentration profile (AUC):
AUC = JCxd f ^ = KC,
y
1 1
2 r  n=o(2n + 1)‘





3. Results and discussion
3.1. Influence of vehicle and dose duration on skin blanching
Selected mean blanching response versus time profiles, as a function 
of dose duration and vehicle, are shown in Figure 1. BMV was applied at the 
same thermodynamic activity (80 % of saturation) in each formulation. The 
chromameter readings were baseline-adjusted and untreated control site 
corrected and are expressed as Aa values. The blanching response 
increased with time for all formulations post-removal reaching a maximum 
after 4 - 6 hours. It would appear, therefore, that drug taken up into the SC 
during the application period was still being released to the site of 
vasoconstrictive response post-removal of the delivery system, a 
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Figure 1: Selected blanching response (Aa) versus time profiles provoked by 
BMV delivered in MCT, LMO, ME and TCL following 2-h ■, 4-h □  and 6-h •  
dose durations. Mean ± SD, n = 6.
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The skin blanching response increased with increasing dose duration. 
Analysis of variance indicated that both the vehicle and the dose duration 
had a significant influence on the AARC values (P < 0.05, two-way ANOVA). 
Figure 2 summarizes these results and shows clearly that the drug delivered 
from LMO shows the lowest pharmacodynamic response at all investigated 
dose durations. On the other hand, the blanching response profiles induced 
by BMV delivered from MCT, ME and TCL were similar, and not significantly 
different from each other. While these latter findings would be consistent with 
the anticipated equivalence of delivery from vehicles containing the drug at 
similar thermodynamic activities, the poorer performance of LMO, which was 
not seen in earlier work [23], suggests that this formulation is retarding BMV 
transport in some way. However, because these conclusions are based on 
measurements of a pharmacodynamic response, which is known to be 
saturable (as is clearly seen from Figure 2), an independent approach to 
evaluate drug delivery is desirable and comprises the justification for the 













Figure 2: Derived AARC values as a function of dose duration and vehicle. 
Mean ± SD, n = 6. Significant differences (P < 0.01) relative to the reference 
formulation (MCT) are shown by the double asterisks.
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3.2. Influence of vehicle on drug uptake into SC
Uptake of BMV from the different vehicles into the SC, determined by 
tape-stripping, yielded the results collected in Figure 3 for MCT (the 
reference formulation), ME and TCL. Data from LMO could not be obtained 
because the levels of drug extracted from the tape-strips were not 
quantifiable. Fitting Eq. 1 to the profiles generated individual values of K and 
D/L2, the means (± SD) of which are in Table 3. AUC values were calculated 
from these parameters using Eq. 2 and are also included in Table 3. BMV 
delivery was significantly different between all formulations with TCL > ME > 
MCT (ANOVA, p < 0.0001). In terms of AUC, TCL out-performed MCT by a 
factor of more than 60-fold, while ME achieved a 5-fold improvement relative 
to the reference formulation. Interestingly, the values of K and D/L2 deduced 
from the concentration profiles were not significantly different between MCT, 
ME and TCL (Table 3). In contrast, the deduced saturation concentrations of 
BMV in the SC (CSlsc) were highly vehicle-dependent implying that 
components of the ME and TCL formulations had also been taken up into the 
SC in sufficient quantities to alter the drug’s solubility in the barrier. Such 
behaviour has been previously reported for Transcutol® [24-26] and for other 
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Figure 3: BMV concentration profiles across the SC following a 2-hour 
application of the drug at 80 % of saturation in three different vehicles: MCT, 
ME and TCL. The individual profiles from 6 volunteers are shown, together 
with the best fits to the data of Eq. 1.
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Table 3: Tape-stripping experimental results (mean ± SD, n = 6) for BMV 
delivered from 4 vehicles following a 2-hour application. The drug 
concentration in each formulation equalled 80 % of its saturation level.
Vehicle Cv [mg/ml] Ka D/L2 [h1]3 Cs,sc [mg/ml] AUC [mg/cm3]c
MCT 1.7 0.83 ± 0.24 0.058 ±0.013 1.68 ± 0.49* 0.51 ±0.18*
ME 9.3 0.78 ±0.10 0.056 ± 0.021 9.13 ±1.15* 2.61 ± 0.67*
TCL 100.8 1.04 ± 0.24 0.042 ± 0.028 131.07 ±30.78* 32.51 ± 13.25*
LMO 0.0017 n.d.d n.d.d - n.d.a
aObtained by fitting experimental data to Eq. 1. 
bCs,sc =  K *C Siv.
cFrom Eq. 2 using the corresponding value of K and D/L2.
dNot determined as BMV could not be quantified in tape-strip extracts.
^Significantly different from each other (p < 0.0001).
3.3. Influence of drug concentration applied on skin blanching
The first series of vasoconstrictor experiments, taken together with the 
tape-stripping results, strongly suggested that the pharmacodynamic 
response was saturated when BMV was applied at 80 % of its maximum 
thermodynamic activity. Therefore, a second set of experiments was 
performed, using the MCT and ME formulations, to examine skin blanching 
when the drug was administered at a lower dose. A single dose duration of 4 
hours was chosen and the vasoconstriction was followed over the next 24 
hours. The results show a clear concentration dependence of the response, 
as has been previously suggested [28]. Figure 4 expresses the data in terms 
of the AARC as a function of either the BMV concentration in the vehicle or 
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Figure 4: Skin blanching response (AARC) as a function of (A) BMV 
concentration Cv, and (B) degree of saturation in the vehicles studied (MCT 
(■) and ME (O)) following a 4-hour application. Mean ± SD, n = 6.
3.4. Influence of drug concentration applied on uptake into the SC
It was then logical to determine whether BMV delivery into the SC 
showed a concentration dependence and to determine the nature of the 
relationship. Again, using the MCT and ME vehicles, the SC uptake of drug 
was evaluated as a function of concentration in the formulation. The results, 
following a 2-hour application are summarized in Figure 5 (and Figure 3) and 
Table 4. The lowest concentrations considered were those that resulted in 
quantifiable amounts of drug in the tape-strips; for this reason, only one other 
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Figure 5: BMV concentration profiles across the SC following a 2-hour 
application of the drug in MCT and ME vehicles at different concentrations. 
The individual profiles from 6 volunteers are shown, together with the best fits 
of the data to Eq. 1
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It is first noted that the estimated values of K, D/L2 were not 
significantly different from those derived from the results for the vehicles 
which contained BMV at 80 % of its saturation level (Table 4). In contrast, the 
AUC values were decreased when the drug was applied at lower 
concentrations, with the reductions observed being more or less proportional 
to the corresponding change in BMV thermodynamic activity. For example, 
an 8-fold decrease in BMV level in the MCT vehicle resulted in an 
approximately order of magnitude reduction in AUC; similarly, when the drug 
concentration in ME was lowered by ~ 60-fold, the AUC decreased by about 
a factor of 80. It follows that, unlike the skin blanching response, drug uptake 
into the SC from a vehicle, in which the compound is below its solubility, is 
not saturable.
Table 4: Tape-stripping experimental results (mean ± SD, n = 6) for BMV 
delivered from MCT and ME vehicles following a 2-hour application. The drug 









[m g /m l]b
A U C C
[m g/cm 3]
MCT 1.7 0.80 0.83±0 .24 0.058±0.013 1.68±0.49 0.51±0.18
0.21 0.10 0 .80±0.29 0.036±0.020 1.69±0.61 0.05±0.02*
ME 9.3 0.80 0 .78±0.10 0.056±0.021 9 .13±1 .15 2.61 ± 0 .6 7
1.2 0.10 0 .5 8 ± 0 .1 1 0.025±0.016 6.81 ±1.30 0.17±0.08*
0.15 0.013 0.59±0 .33 0.042±0.024 6.95±3.96 0.03±0.01*
Obtained by fitting experimental data to Eq. 1
bCs,sc= K-CS)v .
cFrom Eq. 2 using the corresponding values of K and D/L2.
*Significantly different (P < 0.05) from the corresponding value at 0.80-Cs,v-
This conclusion is substantiated when the skin blanching AARC is 
plotted against the SC uptake AUC determined by tape-stripping (Figure 6). 
When all relevant data are included (i.e., one concentration for TCL, two for 
MCT and three for ME), it is clear that the delivery of BMV into the SC is 
affected by both the thermodynamic activity of the drug and by specific
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vehicle-skin interactions. No evidence for saturation of the barrier can be 
identified. In contrast, despite a nearly three order change in AUC, the 












AUC for SC uptake [mg/cm3]
Figure 6: Skin blanching AARC (determined after a 4-hour dose duration) 
plotted against the corresponding AUC for SC uptake determined by tape- 
stripping after a 2-hour application. Data for BMV delivered from MCT (closed 
squares), ME (open squares) and TCL (closed triangles) are shown. Mean ± 




This work demonstrates that the evaluation of topical BA is complex 
and may be sensitive to the methodology employed. While the 
vasoconstrictor assay has been employed extensively for corticosteroids, the 
saturable nature of the response means that results from such experiments 
must be analysed with care (as indeed they have been in most occasions in 
the past). The tape-stripping, or DPK approach, would appear to offer a 
reliable metric with which to quantify transfer of drug from the vehicle to the 
SC. The critical validation of this measure to clinical outcome remains a long­
term objective that will probably be achieved on a case by case (or drug 
class by drug class) basis. Methodological questions remain here as well; for 
example, the SC recoveries are dependent upon the surface cleaning 
procedure at the end of the application period being both efficient and benign 
(i.e., not encouraging penetration). Further work is essential to explore this 
question, in particular the potential significance of formulation which may 
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Abstract
Objective: To compare the in vivo distribution profiles of betamethasone 17- 
valerate (BMV) across the stratum corneum (SC) following (a) delivery from 
gelled and un-gelled formulations, and (b) two different skin cleaning 
procedures at the end of the application period.
Methods: BMV was dissolved in gelled and un-gelled vehicles comprising 
either medium chain triglycerides (MCT) or a brand microemulsion (ME). The 
BMV concentration was adjusted to 80 % of the saturation level and applied to 
the ventral forearm of healthy human subjects. After a 2-hour application, the 
treated skin site was cleaned either with a dry paper towel, or by an isopropyl 
alcohol swab, and the SC was then progressively removed by repeated 
adhesive tape-stripping.
Results: The distribution profiles of BMV across the SC showed that drug 
delivery from the ME was significantly superior to that from MCT. When the 
skin surface was cleaned by dry-wiping, the areas under the SC concentration 
versus normalized position within the SC curve (AUCs) of the gelled 
formulations, respectively, were 2.54 (± 0.69) and 0.53 (± 0.18) mg/cm3; for 
the un-gelled formulations, the corresponding AUCs were significantly 
smaller, but showed the same relative difference (5 to 6-fold) between the two 
vehicles 0.97 (± 0.42) and 0.17 (± 0.10) mg/cm3. Removing excess
99
Chapter 4
formulation more aggressively with isopropyl alcohol resulted in AUCs for ME 
and MCT, respectively, of 0.54 (± 0.16) and 0.20 (± 0.12) mg/cm3.
Conclusion: Assessment of the SC distribution profile of BMV showed 
reasonable reproducibility and a clear ability to distinguish between the two 
formulations. The gelling agent and the method of surface cleaning had a 
significant influence on the apparent extent of drug delivered and on the 
deduced, apparent partition coefficient. Excess gelled formulation may be 
trapped in the skin ‘furrows’ and requires an efficient skin cleaning procedure 




The tape-stripping, or dermatopharmacokinetic (DPK), method is 
attracting increasing attention as a method with which to assess the rate and 
extent of topical drug bioavailability in the stratum corneum (SC) [1-3]. This 
approach, first described by the U.S. Food and Drug Administration (FDA), 
has been proposed for the bioequivalence testing of topically applied drugs
[4]. In 2002, however, the Draft Guidance [5] was withdrawn because of 
doubts regarding the reproducibility between laboratories and, currently, the 
method is being re-evaluated and improved [6].
The DPK concept involves determination of the amount of drug present 
in the SC as a function of time post-application and post-removal of the 
formulation under examination. A key experimental requirement before this 
evaluation is made is to ensure that the residual formulation on the skin 
surface is completely removed before tape-stripping is commenced. The 
cleaning procedure must be efficient, but not so aggressive as to ‘drive’ 
material into the barrier nor to extract it therefrom. Clearly, different types of 
formulation pose different levels of challenge: for example, it might be 
anticipated that a simple lotion will be easier to clean off than an oleaginous 
ointment. The SC surface is not flat; it possesses macroscopic furrows, which 
run parallel to the surface of the skin [7]. It has been argued that the 
quantified amount of drug in the SC tape-strips will include the portion 
deposited in ‘furrows’ as well as that which has penetrated into the SC. The 
putative excess formulation in the ‘furrows’ may complicate the interpretation 
of data obtained after tape-stripping.
The aim of this study, therefore, was to investigate whether the 
cleaning procedure of the treated skin site before stripping altered the DPK 
profile of a typical topical drug (betamethasone 17-valerate) applied in two 
different formulations. Specifically, cleaning the surface with a dry paper towel 
(as described by the FDA) was compared to wiping with an isopropyl alcohol 
swab. In addition, the SC concentration profiles of the same drug, resulting 
from the administration of the same formulations, which were either applied as 




2. Materials and methods
2.1. Materials
Betamethasone 17-valerate (BMV) (Crystal Pharma, Boecillo, Spain) 
was dissolved either in the reference vehicle consisting of medium chain 
triglycerides (MCT) (Mygliol 812 N, Synopharm, Barsbuttel, Germany) or in 
the microemulsion Mikro 100® (ME) (Sebapharma, Boppard, Germany). When 
appropriate, MCT and ME were gelled with 15 % (w/w) polypropylene, and 
10 % (w/w) Aerosil 200® (Sigma-Aldrich, Steinheim, Germany), respectively. 
The BMV concentration was adjusted to 80 % of the saturation level Cs,v (i.e., 
to a constant thermodynamic activity), equivalent to 1.7 mg/ml in MCT and 9.3 
mg/ml in ME [8].
2.2. Tape-stripping procedure
6 healthy volunteers, 4 female, 2 male (26 - 41 years of age), with no 
history of skin disease, participated in the study, which was approved by the 
local research ethics committee (Salisbury Research Ethics Committee). 
Informed consent was obtained from each subject.
600 pi of the gelled formulations were applied using a 1.8 cm diameter 
Hill Top Chamber® (Hill Top Research, Cincinnati, OH, USA) on the forearm, 
at least 4 cm from either the wrist or the bend of the elbow. In a first series of 
experiments, after an application time of 2 or 6 hours, the SC at the treated 
skin site was cleaned with a dry paper towel. Then, the SC was progressively 
removed by repeated adhesive tape-stripping (Scotch Book Tape, 3M, St. 
Paul, MN, USA). In a second set of studies, the same formulations were 
applied and the same procedure adopted, except that the skin surface 
cleaning involved first wiping with a dry paper towel followed by twice wiping a 
70 % v/v isopropyl alcohol swab (Sterets swab, Seton Healthcare, Oldham, 
UK) across the treated skin site. In a third protocol, the MCT and ME 
formulations were applied as un-gelled liquids. A foam tape (3M, St. Paul, 
MN, USA), into which a 2.0 cm diameter hole had been cut, acted as a 
template to constrain the vehicles, and the system was covered by an 
occlusive tape (Blenderm™, 3M, Neus, Germany) to prevent any loss. After a
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2-hour application, the template was removed and excess formulation was 
cleaned away with a dry paper towel.
Briefly, the tape-stripping procedure involved the following steps. A 
piece of polypropylene foil, into which a predefined hole had been cut, was 
placed onto the cleaned, treated skin site and affixed by a piece of self- 
adhesive tape. This template ensured that all tape-strips were removed from 
the same site. The tape (2.5 x 2.5 cm) was applied to this template, pressed 
down with a constant pressure (140 g/cm2) using a weighted rolier and then 
removed. Up to 20 strips were taken from each treated site, such that the SC 
was never completely removed. To check skin barrier function, transepidermal 
water loss (TEWL) measurements were performed (AquaFlux V4.7, Biox 
Systems Ltd., London, UK) during the stripping procedure, which was stopped 
if TEWL reached 60 g/m2h. Each tape was carefully weighed before and after 
stripping on a 10-pg precision balance (Mettler AT 261, Greifensee, 
Switzerland) to determine the mass and thickness of the SC layer removed 
[9]. BMV in the tape-strips was subsequently extracted quantitatively and 
analysed by high-performance liquid chromatography (HPLC) (see method 
below). The amount of BMV on each strip could then be converted to a 
concentration within that removed layer of the SC.
To calculate the total thickness of the SC, the same tape-stripping 
procedure was performed at an adjacent, untreated skin area with periodic 
measurements of TEWL after each tape-strip [9]. Pre-weighed tapes were 
used which were re-weighed after a SC layer had been detached to assess 
the amount of SC removed. From this mass, and knowing the stripping area 
and the density of the SC [10], it was possible to calculate the total thickness 
of the SC from the x-axis intercept of a graph of 1/TEWL versus the 
cumulative thickness of the SC removed. In this way, the drug concentration 
profile across the SC could be displayed in a consistent fashion for all 
subjects, as a function of relative position (or depth) into the barrier.
2.3. Extraction and HPLC analysis of BMV
Each tape was placed into a 2 ml tube, and was extracted with 1.0 ml 
of 60:40 (v/v) acetonitrile/water by shaking overnight. Validation of the
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extraction process involved spiking tape-stripped samples of untreated SC 
with 20 pi of a solution of known drug concentration. Drug recovery was 
96.9 ± 3.4 % (n = 5). BMV in the various samples was quantified by HPLC 
(Dionex, Sunnyvale, CA, USA) with UV detection at 240 nm using a 
Lichrospher® 100 RP-18 column (4 x 125 mm) (Hichrom, Reading, UK). The 
mobile phase was degassed acetonitrile/water (60:40 v/v) delivered at a flow 
rate of 1 ml/min in a 50-pl sample loop. The retention time of BMV at 25 °C 
was ~ 3.8 minutes. A calibration curve was generated using solutions of the 
pure compound at 5 different concentrations. The detection limit was 0.03 
pg/ml. The amount of BMV recovered from the tape-strips was expressed in 
terms of amount of drug per unit SC volume (mg/cm3).
2.4. Analysis of the SC distribution profile
The SC concentration (Cx) versus normalized depth (x/L) profiles of 
BMV were fitted to the appropriate solution of Fick's second law of diffusion
The boundary conditions necessary are: (i) the SC is free of drug at 
t = 0, (ii) the drug concentration at the skin surface is constant (infinite dose 
conditions), and (iii) the viable epidermis at the lower surface of the SC 
provides perfect sink conditions for the drug. Cv is the BMV concentration in 
the vehicle. From the best fit of the experimental values to Eq. 1, the SC- 
vehicle partition coefficient (K) and the diffusivity parameter (D/L2) across the 
SC of pathlength L, were obtained. Subsequently, using the derived 
parameters, K and D/L2, Eq. 1 was integrated across the SC thickness (i.e., 
from x/L = 0 to x/L = 1) to yield the area under the concentration profile (AUC).
(Eq. 1) [11]:
Cx = KCV 1--^ ---f;-s in (n7c-^ )exp(--5-n27i2t) 





The derived AUC values were used to compare the relative 
bioavailability of BMV from the two vehicles and from their quotient 
(A U C me/A U C mct), a  penetration enhancement factor (E F ) was calculated.
2.5. Statistics
Statistical differences were assessed by two-tailed, Student’s t-test and 
by ANOVA, followed by a Bonferroni's multiple comparison test, using 
GraphPad Prism 4.01 software (San Diego, CA, USA).
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3. Results and discussion
Several factors, such as skin hydration, vehicle composition, cohesion 
between corneocytes, and inter-individual differences in total SC thickness 
[12-15], can influence the amount of SC that is removed by a single tape-strip. 
It follows that this quantity is not linearly proportional to the number of tape- 
strips removed and that normalization of the SC thickness removed is a 
prerequisite to facilitate comparison between subjects and between 
formulations.
The individual SC distribution profiles of BMV after a 2-hour application 
time of the gelled MCT and ME formulations are in Figure 1. The ME clearly 
and significantly (two-tailed t-test, P < 0.05) increased the extent of drug 
delivery into the SC, relative to that achieved from the MCT vehicle, as 
reflected in the AUCs observed: 2.61 (± 0.67) and 0.51 (± 0.18) mg/cm3 for 
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Figure 1: SC distribution profiles of BMV delivered from gelled MCT and ME 
formulations following a 2-hour application. The skin surface was cleaned by 
wiping with a dry paper towel. The best fits of Eq. 1 to the individual 
experimental data points are shown (n = 6).
When the same formulations were administered for a longer period of 6 
hours, BMV from both MCT and ME penetrated further into the SC and the 
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Figure 2: SC distribution profiles of BMV delivered from gelled MCT and ME 
formulations following a 6-hour application. The skin surface was cleaned by 
wiping with a dry paper towel. The best fits of Eq. 1 to the individual 
experimental data points are shown (n = 6).
Fitting the data to Eq. 1 allowed values of the partitioning (K) and 
diffusivity (D/L2) parameters to be derived from the experiments performed 
after drug application times of 2 and 6 hours. These results and the AUCs, 
which were determined as described above, are collected in Table 1. It was 
also possible, using the K and D/L2 parameters from the 2-hour experiments 
to predict, using Eq. 2, the AUCs anticipated following a longer application 
period of 6 hours. These calculations are also in Table 1.
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Table 1: Partitioning and diffusivity parameters, as well as measured and 
predicted AUCs, and calculated saturation level of BMV in the SC, from the 
drug concentration profiles following application of gelled MCT and ME 
formulations to human volunteers (mean ± SD, n = 6).
Formulation MCT MCT ME ME
Application time [h] 2 6 2 6
Ka 0.83 ± 0.24 0.77 ±0.18 0.78 ±0.10 1.01 ±0.26
D/L2 [h'1]a 0.058 ±0.013 0.037 ±0.013 0.056 ± 0.021 0.036 ±0.012
K-CSjV = CS)Sc (mg/ml)b 1.7 ±0.5 1.6 ±0.4 9.1 ±1.2 11.8 ±3.0
AUCexpt (mg/cm3)c 0.51 ±0.18 0.58 ±0.14 2.61 ± 0.67 4.18 ± 1.27
AUCpred (mg/cm3)d - 0.68 ± 0.21 - 3.38 ± 0.65
aDeduced from the fit of Eq. 1 to the experimental distri bution profiles.
bCS(sc = calculated saturation level of BMV in the SC. 
cDetermined from Eq. 2 with the deduced values of K and D/L2.
Predicted from Eq. 2 using the values of K and D/L2 deduced from the 2-hour data.
There were no significant differences (ANOVA, P > 0.05) between the 
deduced values of either K or D/L2 for MCT and ME following either 2 or 6 
hours of BMV delivery. However, there was a significant enhancement of drug 
uptake into the SC from ME relative to MCT: EF values were 5.6 (± 2.2) and 
7.6 (± 2.9) at 2 and 6 hours, respectively. This was the result (see Table 1) of 
a significantly increased apparent saturation level of BMV in the SC caused, 
presumably, by the concomitant penetration of ME constituents into the 
barrier. This phenomenon has been reported previously for ibuprofen 
delivered from vehicles containing different proportions of propylene glycol 
and water [16,17]. The predicted AUCs at 6 hours based on the derived 
values of K and D/L2 from the 2-hour experiments were in good agreement 
with the experimental findings for BMV uptake from both formulations. This 
confirms the potential of the technique, as has been proposed [18,19], to 
reduce the number of measurements necessary, for example, to establish 
bioequivalence between different drug products.
The results from the second set of experiments, in which the skin was 
more aggressively cleaned with an isopropyl alcohol swab, following a 2-hour
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application of the gelled M CT and ME formulations, are in Figure 3. Similarly, 
Figure 4 presents the SC uptake profiles of BMV, when applied as un-gelled 
(liquid) formulations in the third series of studies; in this case, skin surface 
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Figure 3: SC distribution profiles of BMV delivered from gelled MCT and ME 
formulations following a 2-hour application. The skin surface was cleaned 
using an isopropyl alcohol swab. The best fits of Eq. 1 to the individual 
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Figure 4: SC distribution profiles of BMV delivered from un-gelled MCT and 
ME formulations following a 2-hour application. The skin surface was cleaned 
with a dry paper towel. The best fits of Eq. 1 to the individual experimental 
data points are shown (n = 6).
Analysis of these two sets of results using Eqs. 1 and 2 generated the 
additional information (partitioning and diffusivity parameters, AUCs, 
saturation levels in the SC and EFs) collected in Table 2.
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Table 2: Partitioning and diffusivity parameters, as well as measured AUCs, 
and calculated saturation levels of BMV in the SC and enhancement factors 
(EF), from the drug concentration profiles subsequent to a 2-hour application 
to human volunteers (mean ± SD, n = 6) of (i) gelled MCT and ME 
formulations followed by skin surface cleaning with isopropyl alcohol, and (ii) 
un-gelled vehicles followed by skin wiping with a dry paper towel.
Formulation MCT (i) ME (i) MCT (ii) ME (ii)
Experimental conditions Isoprop.8 Isoprop.8 Un-gelledb Un-gelledb
Kc 0.37 ± 0.23 0.26 ±0.10 0.43 ±0 .16 0.46 ± 0.20
D/L2 [h‘1]° 0.049 ± 0.023 0.028 ±0.018 0.023 ±0.018 0.026 ±0.017
K Cs V = CSjSc [mg/ml]d 0.8 ±0 .5 3.0 ± 1.2 0.9 ± 0 .3 5.3 ± 2 .4
AUCexpt [mg/cm3]e 0.20 ±0.12 0.54 ±0.16 0.16 ±0 .10 0.97 ± 0.42
EF - 4.0 ± 3.2f - 6.9 ± 3.4f
aSkin surface cleaned using an isopropyl alcohol swab post-application of gelled 
vehicles.
bSkin surface cleaned using a dry paper towel post-application of un-gelled (liquid) 
vehicles.
cDeduced from the fit of Eq. 1 to the experimental distribution profiles. 
dCSlsc = calculated saturation solubility of BMV in the SC.
6Determined from Eq. 2 with the deduced values of K and D/L2. 
fEF = AUCme/AUCmct-
It is immediately apparent that an isopropyl alcohol wipe of the skin 
surface alters the extent of apparent BMV delivery into the SC. AUCs were 
significantly reduced with respect to the values reported in Table 1. This was 
manifest in an approximately 50 % reduction in the SC-vehicle partition 
coefficients of the drug and a ~ 2-fold lowering in the deduced saturation 
levels of BMV in the SC. The values of D/L2, on the other hand, were not 
significantly affected by the surface cleaning procedure, suggesting that the 
brief exposure of the skin served only to remove better sequestered 
formulation from skin ‘furrows’ and did not artefactually ‘drive’ drug into the 
SC. Nevertheless, the basic differences between BMV delivery from MCT and
113
Chapter 4
ME formulations remained unchanged, with the latter still provoking a 
significant enhancement in uptake.
These conclusions were reinforced by the final experiments which 
considered BMV uptake into the SC from un-gelled, liquid formulations and 
skin cleaning with a dry paper towel. AUCs were again lower, as reflected in 
the lower values of K; in turn, these translated into reduced saturation levels 
in the SC. The order of magnitude of these changes were very similar to what 
had been seen when the gelled vehicles were removed with isopropyl alcohol. 
Clearly, the simpler, dry-wiping procedure is quite effective in removing 
material from deeper regions of the skin’s surface topology for low-viscosity, 
liquid formulations; in contrast, a more aggressive approach is warranted for 
semi-solid products which are typically used in practice.
In summary, therefore, this research has provided further information 
essential for the evolution of the DPK, tape-stripping method as a tool for the 
measurement of bioavailability and bioequivalence. It is clear that quantitative 
comparisons between formulations must be performed ‘on a level playing 
field’ where it is certain that the SC uptake deduced from the analysis of the 
tape-strips is not contaminated by drug formulation trapped in skin ‘furrows’. 
The careful evaluation and validation of an efficient skin cleaning procedure at 
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The stratum corneum (SC) is the outermost layer of the epidermis and 
is primarily responsible for skin’s barrier function [1]. In particular, the SC 
regulates the passive loss of water to the environment [2]. The SC consists of 
more or less parallel layers of proteinaceous corneocytes, interspersed with 
hydrophobic intercellular lipid bilayers [3]. The intercellular SC lipids are 
primarily ceramides (~ 40 % w/w), free fatty acids (~ 10 % w/w), and 
cholesterol (~ 25 % w/w), with a small fraction of cholesterol sulphate and 
triglycerides [4,5]. The SC lipids are believed to be responsible for regulating 
the passive flux of water through the SC from the deeper, highly hydrated 
layers of the epidermis to the surface of the barrier where the moisture 
content is relatively low [6].
On average, water in the SC corresponds to 15 - 20 % of the dry 
weight, but varies according to humidity of the external environment [7]. The 
water content of the SC comprises both that bound in corneocytes and that 
associated with the intercellular lipids. Measurement of skin hydration has 
been used to assess barrier function integrity in vivo [8]. It is also well-known 
that drug penetration can be influenced by skin hydration, which may be 
increased via physical occlusion or by the application of moisturizing or 
oleaginous vehicles [9]. Increased SC hydration may alter partitioning of a 
drug from a formulation and/or the solubility of the drug in the barrier. 
Measurements of transepidermal water loss (TEWL) or of skin hydration are 
useful approaches with which to assess vehicle effects on SC barrier 
function. The latter employs a so-called corneometer which provides a 
relative assessment of skin surface (SC) hydration.
In an earlier in vivo study, the skin blanching and tape-stripping 
methods were used to assess the penetration of betamethasone 17-valerate 
(BMV) from different vehicles [10]. Specifically, a microemulsion, light mineral 
oil and a formulation based on the penetration enhancer, Transcutol®, were 
compared with a reference vehicle which comprised medium chain 
triglycerides (MCT). The tape-stripping results showed that Transcutol® and 




The aims of this pilot investigation, therefore, were to evaluate the 
effect of these same vehicles on skin hydration and to compare the results 
with those from the topical availability measurements.
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2. Materials and methods
2.1. Preparation of the formulations
The vehicles investigated were: light mineral oil (LMO), medium chain 
triglycerides (MCT) (Synopharm, Barsbuttel, Germany), the microemulsion 
Mikro 100® (ME) (Sebapharma, Boppard, Germany) and diethyleneglycol 
monoethyl ether (Transcutol®, TCL) (Gattefosse, Saint Priest, France). LMO 
and MCT were gelled with 15 % polypropylene, ME and TCL with 10 % 
Aerosil 200® (both Sigma-Aldrich, Steinheim, Germany).
2.2. In vivo experiments
Eight healthy, female volunteers (21 - 29 years) participated in the 
study, which was approved by the Ethics Committee of the University of 
Leipzig. MCT was chosen as the reference vehicle because it was not 
expected to exert appreciable effects on the skin [11]. A single, infinite dose 
comprising 250 pi of each formulation, was applied via a 1.2 cm diameter Hill 
Top Chamber® (Hill Top Research Inc., Cincinnati, OH, USA) to the volar 
aspect of the forearm for different dose durations of up to 6 hours. At the end 
of the treatment period, the chambers were removed and excess formulation 
was gently wiped away using a dry paper towel. The amount of moisture in 
the outer layer of the skin (skin hydration) was measured before application, 
immediately after removing the formulation, and then repeatedly over the 
next 40 minutes. The latter was accomplished using a corneometer CM 825® 
(Courage & Khazaka, Cologne, Germany) (Figure 1) mounted on a Multi 
Probe Adapter® MPA 5 (Courage & Khazaka). The apparatus determines the 
relative capacitance of the skin, to a measurement depth of approximately 
10-20 pm, via a probe that consists of two closely juxtapositioned, finger-type 
metal plates. Changes in the water content of the SC, therefore, cause a 
change in the local dielectric constant and hence a proportional change 
(expressed in arbitrary units) in capacitance. A spring in the probe head 
ensures that the latter is reproducibly applied at a constant pressure to the 
skin. At separate skin sites pre- and post-treatment (at 2 hours for all 
formulations, and at 6 hours for MCT and ME), TEWL was measured
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(AquaFlux V4.7, Biox Systems Ltd., London, UK). Five individual 
measurements were performed on each tested skin site and the average 
value was determined. All experiments were carried out under reasonably 
similar conditions of relative humidity (40-60 %) and temperature (20-25 °C).
Figure 1: Skin hydration measured with the corneometer.
2.3. Statistics
Analysis of variance was performed using PRISM 4.01 (GraphPad, 
San Diego, LA). Changes over time with different vehicles were compared 
with a two-way ANOVA followed by an a-adjusted post-hoc Bonferroni test. 




3. Results and discussion
To facilitate comparison between vehicles, the absolute values of skin 
hydration were normalized with respect to the corresponding pre-treatment 
control measurements. The variations of these normalized results, as a 
function of dose duration, are in Figure 2. All vehicles produced a significant 
increase in skin hydration versus the untreated control. Constant levels of 
hydration were reached after 30 minutes application of all vehicles. Extending 
the dose duration up to 6 hours did not elicit any further change in skin 
hydration. ME significantly increased skin hydration relative to MCT after 30 
minutes; on the other hand, TCL significantly lowered skin hydration (again, 
relative to MCT) after a 4-hour application. In a brief parallel experiment 
(dose duration = 30 minutes), it was shown that the elimination of the gelling 
agent did not alter the findings reported in any way (data not shown).





Figure 2: Normalized skin hydration as a function of exposure time to four 
different vehicles (mean ± SD, n = 8). Significant differences (P < 0.01) 
relative to the reference formulation (MCT) are shown by the double 
asterisks.
Recoveries of skin hydration post-removal of the formulations (after an 
exposure duration of 2 hours) are in Figure 3. The initially high values 
diminish quite rapidly to the control level (normalized skin hydration = 1); for 
TCL, however, the decrease was significantly greater, with the normalized
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skin hydration clearly dropping to below 1. It would appear, therefore, that 
TCL is able to draw water from the SC, an effect which may explain its 
deduced ability to increase the solubility of the lipophilic betamethasone 17- 
valerate in the SC [10]. In contrast, the ME vehicle, which also improved the 
steroid’s uptake into the SC (albeit to a much lower extent than TCL) [10,12], 
did not appear to elicit any long-term effect on skin hydration, at least none 
that could be detected at the sensitivity of the corneometer measurements.
T I 1 ' - I1 " ‘ ' —I1 1
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Time post-removal [h]
Figure 3: Normalized skin hydration as a function of time post-removal of 
different vehicles applied for 2 hours (mean ± SD, n = 8). Significant 
differences (P < 0.01) relative to the reference formulation (MCT) are shown 
by the double asterisks.
These conclusions are confirmed by the TEWL results in Figure 4. 
While occlusion for 2 or 6 hours with the MCT and ME formulations caused a 
marked increase in TEWL immediately post-removal (relative to the pre­
treatment control), the effect of TCL was significantly less, effectively 
obliterating the impact of the occlusion period of exposure to the vehicle. 





Figure 4: Normalized TEWL values (post-removal divided by pre-treatment) 
immediately after removal of the different formulations tested (mean ± SD, 
n = 6). Significant differences (P < 0.01) relative to the reference formulation 
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Despite the importance and frequent use of topical glucocorticoids in 
dermatology, their topical bioavailability (BA) and bioequivalence (BE) 
remains difficult to assess. While it is generally agreed that corticosteroid BA 
is poor, a quantitative measure of this key parameter has proven elusive. The 
objective of this thesis, therefore, was to evaluate the potential of two non- 
invasive, in vivo techniques to determine the topical BA of a topical steroid. 
The first, the vasoconstrictor assay, is already accepted by regulatory 
agencies, such as the U.S. Food and Drug Administration (FDA), for BA/BE 
testing. This method is based on the ability of topical glucocorticoids to cause 
visible and quantifiable skin blanching. The second method is the 
dermatopharmacokinetic (DPK) approach using tape-stripping, which is being 
intensively investigated at this time. Betamethasone 17-valerate (BMV) was 
selected as a model corticosteroid and was formulated in several vehicles at 
different levels of saturation.
The vasoconstrictor assay may, in the right circumstances, be a useful 
method to determine the local BA of topical glucocorticoids. The results of the 
vasoconstrictor assay performed with BMV delivered from different vehicles, 
and over a range of different concentrations, resulted in a clear concentration 
dependence of the skin blanching response until saturation occurred (Figure 
1). Subsequently, no further differences between formulations or 
concentrations applied could be detected. As with any pharmacodynamic 
response, this is an potential issue and it is important, therefore, to operate in 
the linear part of the ‘dose-response’ curve whenever quantitative 
conclusions about BA/BE are to be drawn. However, this linear part of the 
‘dose-response’ curve for BMV appeared to be narrow and the variability of 
the pharmacodynamic response was quite high (40 - 60 %); it follows that a 
large number of subjects is needed to identify statistically significant 
differences. It is clear that the vasoconstrictor assay remains some way from 
an absolute measurement of the extent of drug delivery to the skin (at or near 
the target site) and the rate at which this is achieved. Further, it is obviously
131
Conclusions











Figure 1: Skin blanching response (expressed as AARC) as a function of 
BMV concentration applied in two different vehicles (Cv). Mean ± SD, n = 6.
The dermatopharmacokinetic (DPK) approach, using tape-stripping, 
appeared to offer a reliable metric with which to quantify the effective amount 
of drug penetrating into the major barrier for percutaneous absorption, the 
stratum corneum (SC). This technique has the advantage of being applicable 
to a broader range of topical drug classes; it is also simple and relatively non- 
invasive. In 1998, the FDA proposed a Draft Guidance, analogous to the 
pharmacokinetic method of oral drug BA/BE assessment, whereby the drug 
uptake and elimination into and from the SC were to be determined as a 
function of time post-application and post-removal. Although the DPK profiles 
of BMV according to the Draft Guidance showed reasonable reproducibility 
and a clear ability to distinguish between different formulations, some clear 
weaknesses have been exposed: specifically, the similar design of the 
approach to oral BA assessment makes the procedure rather labour- 
intensive, and the lack of quantification of the SC amount removed is 




As a consequence, a critical re-evaluation of the DPK method is in 
progress, with a clear objective to validate the method. Important progress 
has already been made with regard to quantification and standardization of 
the amount of SC removed using tape-stripping such that drug concentration 
profiles across the SC from different volunteers can now be expressed on the 
same scale: that is, as a function of relative position within the SC. Equally, 
dermatopharmacokinetic parameters, characterizing drug partitioning and 
diffusivity into and through the SC, can be deduced and used to quantify, 
respectively, the extent and rate of drug delivery. The normalized distribution 
profiles of BMV across the SC after a 2-hour uptake were, like the DPK 
profiles, sensitive enough to discriminate between formulations and different 
concentrations applied.
The cleaning procedure before tape-stripping has also to be validated 
to ensure that the residual formulation on the skin surface is completely 
removed and that the amount analysed from the tape-strips includes only the 
amount of drug which has penetrated into the SC rather than that which may 
be deposited in skin ‘furrows’. The cleaning procedure, therefore, must be 
efficient, but not so aggressive to ‘drive’ compounds into the SC nor to 
extract it therefrom. It was shown in this thesis that wiping the skin before 
stripping with an isopropyl alcohol swab was much more efficient than 
cleaning with a dry paper towel (as recommended by the FDA). This more 
aggressive cleaning procedure led to a significant decrease (~ 2-fold) in the 
apparent extent of drug delivery into the SC and in the partition coefficient. 
Excess formulation, especially from semi-solids, may be trapped in the skin 
‘furrows’ and could lead to a overestimation of the apparent extent of drug 
delivery into the SC, if not removed completely. A careful evaluation and 
validation of an efficient skin cleaning procedure at the end of the application 
period is, therefore, a pre-requisite. Also the viscosity of the formulation was 
shown to influence the amount of drug recovered on the tape-strips. Liquid 
formulations can be removed more easily from the skin’s surface with a dry- 
wiping procedure, whereas a more aggressive approach is warranted for 
semi-solid vehicles (Figure 2).
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Other techniques, such as optical microscopy or attenuated total 
reflectance Fourier transform infrared spectroscopy, may also prove useful 
for better characterizing the deposition of a formulation and its delivered drug 
(and the efficiency of a cleaning process) on the skin surface. Future 
experiments may usefully apply these methods to complement the work 
already done.
4
Vehicle 1 Vehicle 2
Figure 2: Apparent extent of BMV delivery in the SC (expressed as AUC) 
from two vehicles as a function of the cleaning procedure before tape- 
stripping. Semi-solids cleaned with a dry paper towel (blue), semi-solids 
cleaned with an isopropyl alcohol swab (green), liquids cleaned with a dry 
paper towel (red). Mean ± SD, n = 6.
A weakness of the DPK approach is that the measurement 
‘compartment’ is not always the same as the site of action. It has to be 
assumed, that SC drug levels are directly related to those in the deeper skin 
layers. For steroids, the target receptors are within the viable epidermis and 
dermis, not in the SC. Nevertheless, it seems likely that a formulation, which 
changes drug uptake into the SC, which is the major barrier to steroid 
absorption, should also change the drug’s BA at the site of action. The 
permeation/diffusion of the drug then from the SC into the deeper skin layers 
should be independent of the vehicle and a function primarily of the 
properties of the drug itself (lipophilicity, receptor affinity, etc.).
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An alternative approach, already subject to serious evaluation, and 
one certainly worthy of further consideration and study, is microdialysis. 
While serious technical challenges remain, this method does allow topical 
drug concentrations in regions of the skin close to the site(s) of drug action to 
be determined.
Overall, however, it may be argued that the tape-stripping method, 
while not yet completely optimised, and perhaps more complicated than the 
vasoconstrictor assay, is nevertheless straightforward and relatively easy to 
perform. This technique is sensitive enough to differentiate between 
formulations and between concentrations. With further development, the DPK 
approach may offer a more quantitative and objective strategy for topical BA 
assessment of topical glucocorticoids than the vasoconstrictor assay.
Finally, it is worth considering what else may be necessary to 
enhance further the use of the DPK procedure for routine topical BA/BE 
assessment? The most onerous and time-consuming part of the method is 
the careful weighing of each tape-strip before and after SC removal to 
determine the amount of tissue removed. The gravimetric approach is not 
without problems (static electricity on the tapes, small amounts of SC 
removed, etc.) and a more direct and simple assessment of the amount of 
SC removed would be useful. A spectrophotometric method is one 
alternative, and is based on the determination of the absorbance (scattering, 
reflection and diffraction) of the corneocyte aggregates, attached to the tape, 
in the visible spectral range. This technique also has the potential to quantify 
the drug directly on the tape-strips if it has an absorbance clearly separated 
from those of the SC. Indeed, there have already been some promising 
correlations observed between the weight of SC removed and the 
absorbance at 430 nm of SC stripped off with Tesa tape (No. 5529, 
Beiersdorf AG, Hamburg, Germany) [1,2]. To-date, however, this approach 
has not been fully optimised or characterized.
Some preliminary experiments are therefore been performed to 
evaluate the suitability of the spectrophotometric method to assess the SC 
amount removed using the methods described in this thesis. Scotch Book
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tape 845 (3M, St. Paul, MN, USA) is more adhesive than Tesa tape. In a pilot 
study, the untreated SC of 13 volunteers was tape-stripped and was 
quantified either gravimetrically or by measuring the absorbance 
spectrophotmetrically. On average 20 tape-strips per volunteer were taken to 
ensure that at least 75 % of the SC had been removed (as confirmed by 
transepidermal water loss measurements). The amount of corneocytes 
adhering to each tape was quantified directly on the tape at 430 nm (Lambda 
35 spectrophotometer, Perkin Elmer, Uberlingen, Germany) with an empty 
tape as reference.
Figure 3 shows the UVA/IS spectra of a tape-strip removed from the 
forearm and a blank tape without any SC attached. As the latter indicates 
essentially is no absorbance at 430 nm (as described in the literature for 
Tesa tape as well), the same wavelength was used to determine the amount 
of SC removed by the Scotch Book tape used in this work.
2.00
A 1.0
200.0 400 600 800.0
nm
Figure 3: UVA/IS spectra of a tape-strip without (green line) and with SC (red 
line).
Absorbance at 430 nm was plotted against the thickness of the 
corneocyte aggregates removed on each tape-strip (Figure 4) and linear 
regressions were performed on the results from each subject (Table 1).
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Absorbance increased with the thickness of SC removed, and almost all 
correlations were significant (11 out of 13 have R2 > 0.69).
0.5-
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Thickness SC Removed [pm]
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1.0
Figure 4: Absorbance at 430 nm versus thickness of SC layer removed on 
each tape-strip. Data comprise 256 pooled readings from 13 volunteers.
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Table 1: Calculated slopes, y-intercepts and R2 values following linear 
regression of the datasets from each volunteer.
Volunteer Slope (pm"1) y-intercept R2
1 0.56 0.03 0.92
2 0.25 0.10 0.71
3 0.30 0.12 0.88
4 0.35 0.06 0.86
5 0.36 0.06 0.89
6 0.32 0.05 0.90
7 0.28 0.19 0.40
8 0.18 0.14 0.25
9 0.27 0.16 0.86
10 0.36 0.14 0.73
11 0.23 0.07 0.69
12 0.25 0.05 0.96
13 0.29 0.05 0.87
Mean 0.31 0.09 -
SD 0.09 0.05 -
Nevertheless, there is clearly important variability between subjects, in 
terms of the slopes obtained. It would not be possible, therefore, at this time, 
to define a single proportionality constant with which to convert absorbance 
to a SC thickness. Intra-subject variability has not yet been determined but 
clearly represents an important next step in the evaluation of this approach.
Some effort was made to examine whether the observed variability 
was due to inhomogeneity in the distribution of SC across the surface of the 
tape-strip. The total area stripped in these experiments was 4 cm2, while the 
spectrophotometer beam only interrogates the central 1 cm2 of the sample. 
Consideration of a random selection of tapes revealed that the apparent 
inhomogeneity accounted for less than 8 % of the variability, insufficient to 
fully explain the results, therefore.
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Additional work is obviously needed and, again, microscopic 
examination may be helpful in asking whether the more aggressive Scotch 
adhesive removes more than one SC layer per strip in some subjects. It is 
also sensible to re-consider the value of a more direct, chemical
quantification (i.e., protein assay [3-5]) of the SC on the tape-strips. The latter 
should ultimately be amenable to high-throughput screening, a clear 
advantage if the DPK method is to be used routinely.
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BMV in the various samples was quantified by HPLC (Dionex, 
Sunnyvale, CA, USA) with UV detection at 240 nm using a Lichrospher® 100 
RP-18 column (4 x 125 mm) and pre-column (Hichrom, Reading, UK) The 
mobile phase was degassed acetonitrile/water (60:40 v/v) delivered at a flow 
rate of 1 ml/min in a 50-pl sample loop. The retention time of BMV at 25 °C 
was -  3.8 minutes. A calibration curve was generated using solutions of the 
pure compound at 5 different concentrations (Figure 1). The detection limit 
was 0.03 pg/ml. The quantification limit was 0.1 pg/ml.
y = 13.665x 
R2 = 0,9996
0,2 0,3
BMV concentration in acetonitrile/water 60:40 [mg/ml]
0,4 0,5 0,6
Figure 1: Typical calibration curve for BMV.
2. Tape-stripping protocol
A maximum of three application sites were selected on the forearm of a 
healthy volunteer. The area of each site was approximately 4 cm2. One of 
these application sites was used for the determination of the total stratum 
corneum (SC) thickness; the other two were used for the application of the 
formulations and the determination of the SC drug profiles.
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Site A: Determination of the total SC thickness
Approximately 25 tapes (Scotch® No. 845 Book Tape, 3M, St. Paul, 
MN, USA) were cut into pieces of 2.5 x 2.5 cm2 (1) and allowed to equilibrate 
for at least 12 hours in the laboratory. The weight of each tape was 
determined using a balance with a precision of at least 10-pg (2).
A template (piece of polypropylene foil), into which a 2.0 cm diameter 
hole had been cut, was affixed onto an untreated skin site (3). This template 
ensured a constant skin area. The initial transepidermal water loss (TEWL) of 
this skin area was measured (4) (AquaFlux V4.7, Biox Systems Ltd., London, 
UK).
Subsequently, the SC was progressively removed by repeated 
adhesive tape-stripping. The pre-cut tape was applied to the template (5), 
pressed down 10-times with a constant pressure (140 g/cm2) using a 
weighted roller and then removed with one quick movement (6). The TEWL 
was measured after each tape-strip removed. Tape-stripping was continued
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until the TEWL reached 4-fold the initial value. This was to ensure, that the 
SC was never stripped completely but at least 75 % of the SC was removed.
Each tape was re-weighed after stripping to assess the mass of SC 
removed. From this mass, and knowing the stripping area and the density of 
the SC (1g/cm3), it was possible to calculate the thickness of SC removed 
with each tape. The total thickness of the SC was then calculated from the x- 
axis intercept of a graph of 1/TEWL versus the cumulative thickness of SC 
removed (Figure 2).
0,1 ,
y = -0,0089x + 0,085 
R2 = 0,9929
0  -I i i —  r   -t —
0 2 4 6 8 10
Cumulative SC Thickness Removed (x) [pm]
Figure 2: Plot of 1/TEWL versus cumulative SC thickness removed from a 
volunteer. Total thickness of the SC equals 9.55 pm.
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Site B: Application of a formulation and determination of the drug 
distribution profile across the SC
Approximately 20 tapes per application site were cut into pieces of 
2.5 x 2.5 cm2 and allowed to equilibrate for at least 12 hours before weighing.
600 pi of a gelled formulation was applied using a 1.8 cm diameter Hill 
Top Chamber® (Hill Top Research, Cincinnati, OH, USA) on the forearm, at 
least 4 cm from either the wrist or the bend of the elbow. The chamber was 
fixed to the skin with adhesive tape (Curafix® H, Lohmann & Rauscher, 
Rengsdorf, Germany). An un-gelled, liquid formulation was applied via a foam 
tape (3M, St. Paul, MN, USA), into which a 2.0 cm diameter hole had been 
cut. The foam tape was applied to the forearm (7), a piece of paper towel was 
inserted and the liquid formulation was added (8), finally, the foam tape 
system was covered by an occlusive tape (9) to prevent any loss of the 
formulation.
After the desired application time, the chamber or the foam tape 
system was removed and the SC at the treated skin site was cleaned with a 
dry paper towel or by additional twice wiping a 70 % v/v isopropyl alcohol 
swab (Sterets swab, Seton Healthcare, Oldham, UK). A template (piece of 
polypropylene foil) into which a 2.0 cm diameter hole had been cut was 
placed onto the same cleaned, treated skin site and affixed with self-adhesive 
tape. This template ensured that all tape-strips were removed from the same 
site. Immediately after, the initial TEWL value was measured. Then, a pre­
weighed tape was applied to this template, pressed down 10-times with a 
constant pressure (140 g/cm2) using a weighted roller and then removed with 
one quick movement. Up to 20 strips were taken from each treated site. 
TEWL measurements were performed during the stripping procedure (after 
every 3-5 tape-strips), which was stopped if TEWL reached 60 g/m2/h, or 4
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times the initial TEWL value. This was to ensure, that the SC was never 
stripped completely but at least 75 % of the SC was removed. Each tape was 
carefully weighed again after stripping to determine the mass and thickness of 
SC removed. Afterwards, each tape was inserted into a 2 ml glass vial and 
the drug was extracted with an appropriate solvent mixture by overnight 
shaking. The solution obtained was analysed for drug by HPLC.
Data elaboration
The drug concentration in each tape-strip (mg/cm3) was plotted as a 
function of its position (x) within the normalized SC thickness (L) (Figure 3). 
These profiles were fitted to the appropriate solution of Fick’s 2nd law of 
diffusion. From the best fit of the experimental data to this Equation, the SC- 
vehicle partition coefficient and the diffusivity parameter of the drug across 









0,2 0,4 0,6 0,8
Position within normalized SC thickness (x/L)
Figure 3: Typical BMV distribution profile across the SC.
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3. Vasoconstrictor assay protocol
A maximum of ten application sites were selected on the forearm of a 
healthy volunteer. The area of each site was approximately 2 cm2. At least 
one of these application sites was used for the drug free vehicle; the other 
ones were treated with drug containing formulations.
The vasoconstrictor assay was carried out according to the “staggered 
application with synchronized removal” method of the FDA Guidance “Topical 
Dermatologic Glucocorticoids -  In vivo Bioequivalence”. Before applying the 
formulations, the application areas on the forearms were marked with a 
permanent marker. This was to ensure to measure always the same skin 
sites. The 1.2 cm diameter Hill Top Chambers® (Hill Top Research, 
Cincinnati, OH, USA) were filled with the formulations, which content 
approximately 250 pi of volume. Then, the filled chambers were applied to the 
forearm in a staggered manner and affixed with adhesive tape (Curafix® H, 
Lohmann & Rauscher, Rengsdorf, Germany). The drug application sites were 
on the volar forearm, at least 4 cm from the wrist and 4 cm from the 
antecubital fossa. The amounts of the formulations applied ensured infinite 
dose conditions.
The formulations were applied to the skin for dose durations of 2, 3, 4, 
5 and 6 hours. The drug free vehicles were also applied as control for 6 
hours. The chambers were then removed simultaneously and excess 
formulation was cleaned off with a dry paper towel. The skin blanching 
response of the treated skin sites (with formulations and with the control) was 
assessed via a chromameter (CR-300, Minolta, Ahrensburg, Germany) using 




The chromameter was calibrated using an optically white plate 
immediately before use. Baseline readings were taken at all sites prior to the 
application of the formulations. The a-scale readings for each drug application 
site were adjusted for the baseline value and the control and expressed as 
the change in this parameter (Aa). As the a-scale values decrease with 
increasing skin blanching, Aa is negative. The degree of response was 
therefore expressed as the (positive) area above the response curve (AARC) 
using the trapezoidal rule.
4. UV spectrophotometer method
The tape-stripping procedure was performed as described above with 
the following modifications. The template had a size of ~ 5 x 4 cm2, in which a 
2 x 2  cm2 square had been cut. The tapes for stripping were cut into 
rectangles of 4.0 x 2.5 cm2.
After weighing, the same tapes were fixed on a sample holder and the 
holder with the tape was then transferred into the spectrophotometer, which 
was equipped with a quadratic beam (1 x 1 cm2). The absorbance of the SC 
attached to the tape was quantified at 430 nm (Lambda 35 
spectrophotometer, Perkin Elmer, Uberlingen, Germany) with an empty tape 
as reference. The absorbance at 430 nm was taken as a measure because 
the spectral range around this wavelength is sufficient apart from the 
absorbance bands of other components of the system. The absorbance of the 
tape does not disturb the absorbance of the SC. The homogeneous 





Table 1: Cumulative SC thickness removed, normalized SC thickness 
removed and corresponding TEWL values after tape-stripping at an untreated










0 0,00 0,00 8,73 0,00 0,00 8,08
1 0,95 0,06 8,87 0,22 0,02 9,23
2 1,82 0,12 8,78 1,50 0,14 8,89
3 2,47 0,16 8,93 2,05 0,19 9,66
4 3,00 0,20 9,14 2,62 0,24 9,33
5 3,40 0,22 9,30 3,12 0,29 9,66
6 4,03 0,26 9,25 3,42 0,32 10,27
7 4,53 0,30 9,48 3,75 0,35 10,59
8 5,03 0,33 10,05 4,17 0,39 11,01
9 5,43 0,36 11,05 4,52 0,42 11,89
10 6,00 0,39 11,98 4,90 0,46 11,73
11 6,45 0,42 12,74 5,53 0,51 13,86
12 6,73 0,44 13,37 5,80 0,54 14,08
13 7,23 0,47 14,81 6,23 0,58 16,05
14 7,55 0,50 16,16 6,50 0,60 16,88
15 7,93 0,52 16,20 6,80 0,63 19,65
16 8,50 0,56 17,90 7,15 0,67 23,03
17 8,90 0,58 17,99 7,55 0,70 28,26
18 9,43 0,62 18,26 7,75 0,72 36,14
19 9,80 0,64 22,00 7,73 0,72 46,55
20 10,20 0,67 24,29 8,08 0,75 69,25
21 10,95 0,72 26,86
22 11,53 0,76 36,83
23 11,95 0,79 50,71












0 0,00 0,00 13,11 0,00 0,00 11,01
1 0,43 0,04 13,62 0,60 0,05 11,70
2 0,83 0,07 13,73 1,02 0,09 11,31
3 1,15 0,10 13,04 1,53 0,14 11,57
4 1,95 0,17 13,73 2,07 0,19 12,23
5 2,43 0,21 13,43 2,77 0,25 12,66
6 2,85 0,24 13,54 3,28 0,29 11,93
7 3,35 0,29 15,06 3,76 0,34 13,69
8 3,77 0,32 15,80 4,01 0,36 13,98
9 4,32 0,37 16,43 4,39 0,39 14,34
10 4,82 0,41 16,50 4,87 0,44 16,19
11 5,25 0,45 17,72 5,38 0,48 16,67
12 5,50 0,47 19,25 5,73 0,51 19,82
13 6,10 0,52 22,68 6,18 0,55 20,21
14 6,40 0,55 25,96 6,46 0,58 21,68
15 6,77 0,58 27,68 6,78 0,61 24,54
16 7,22 0,62 35,79 7,10 0,64 27,38
17 7,50 0,64 42,65 7,35 0,66 34,15
18 7,75 0,66 45,53 7,58 0,68 40,88















0 0,00 0,00 9,50 0,00 0,00 7,63
1 0,86 0,08 8,36 0,48 0,05 7,75
2 1,46 0,13 8,91 0,95 0,09 7,70
3 2,20 0,20 8,90 1,50 0,15 8,19
4 2,64 0,24 9,99 1,95 0,19 8,46
5 3,21 0,29 10,25 2,45 0,24 8,73
6 3,69 0,33 11,27 2,95 0,29 9,37
7 4,11 0,37 12,03 3,35 0,33 9,89
8 5,06 0,45 13,03 3,85 0,38 10,25
9 5,57 0,50 13,89 4,33 0,42 10,95
10 5,98 0,54 15,73 4,73 0,46 11,81
11 6,40 0,57 18,38 5,05 0,49 12,41
12 7,03 0,63 20,49 5,38 0,53 12,94
13 7,42 0,66 23,32 5,88 0,57 15,16
14 7,77 0,70 30,06 6,25 0,61 16,71
15 8,24 0,74 38,23 6,65 0,65 22,98
16 8,69 0,78 49,79 6,98 0,68 29,94



















0 0,00 0,00 15,45 0,00 0,00 13,02
1 0,45 0,05 15,48 0,64 0,05 13,84
2 1,02 0,11 16,19 1,21 0,10 14,67
3 1,38 0,14 16,48 2,23 0,18 13,79
4 1,54 0,16 16,11 2,80 0,23 15,00
5 1,90 0,20 17,22 3,15 0,26 16,00
6 2,06 0,21 17,78 3,57 0,29 16,42
7 2,54 0,26 19,73 4,27 0,35 17,92
8 2,83 0,29 20,77 4,49 0,37 18,55
9 2,97 0,31 24,44 4,81 0,39 19,02
10 3,20 0,33 21,92 5,06 0,41 19,72
11 3,47 0,36 27,43 5,35 0,44 21,08
12 3,70 0,39 27,45 6,05 0,50 23,20
13 3,99 0,42 30,74 6,24 0,51 24,64
14 4,17 0,43 32,55 6,40 0,52 24,74
15 4,33 0,45 42,38 6,46 0,53 26,11
16 4,67 0,49 52,89 6,68 0,55 27,32
17 6,97 0,57 29,90
18 7,19 0,59 32,04
19 8,09 0,66 38,50
20 8,47 0,69 44,80
21 9,04 0,74 56,37
22
23










0 0,00 0,00 9,21 0,00 0,00 10,38
1 1,15 0,12 8,59 0,70 0,07 10,14
2 1,53 0,16 9,29 1,31 0,14 10,55
3 2,04 0,21 9,27 1,78 0,19 10,94
4 2,42 0,25 10,77 2,17 0,23 11,06
5 2,83 0,30 10,42 2,85 0,30 11,41
6 3,34 0,35 12,21 3,24 0,34 11,58
7 3,76 0,39 11,96 3,53 0,37 12,65
8 4,07 0,43 12,80 3,86 0,41 13,16
9 4,49 0,47 13,54 4,13 0,43 12,76
10 5,25 0,55 16,24 4,45 0,47 13,80
11 5,73 0,60 17,81 4,74 0,50 14,76
12 5,89 0,62 21,68 5,04 0,53 15,67
13 6,24 0,66 23,88 5,37 0,56 16,64
14 6,40 0,67 28,16 5,60 0,59 17,72
15 6,65 0,70 39,10 5,82 0,61 19,78
16 5,99 0,63 21,90
17 6,23 0,65 23,98
18 7,19 0,76 28,73
19 7,59 0,80 31,33
20 8,13 0,86 34,35
21 8,42 0,89 37,71
22
23








0 0,00 0,00 12,15
1 0,45 0,05 12,37
2 0,72 0,08 12,65
3 0,98 0,10 12,84
4 1,35 0,14 14,10
5 1,68 0,18 13,82
6 1,98 0,21 14,76
7 2,60 0,27 16,65
8 2,80 0,29 16,95
9 3,42 0,36 17,67
10 3,75 0,39 18,40
11 4,05 0,42 19,62
12 4,32 0,45 22,63
13 4,52 0,47 22,20
14 4,80 0,50 24,08
15 5,05 0,53 23,93
16 5,65 0,59 29,31
17 6,00 0,63 30,75
18 6,50 0,68 34,38
19 6,82 0,71 42,17
20 7,20 0,75 49,13
21 7,27 0,76 57,68
22
23
Total thickness [uml 9,55
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Table 2: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 80 % of saturation in MCT. Skin surface was 
cleaned using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,080 1,463 0,054 1,150 0,069 1,767
0,196 1,043 0,144 0,545 0,202 1,494
0,253 0,906 0,207 0,816 0,302 1,223
0,297 0,833 0,256 0,632 0,363 1,151
0,335 0,675 0,299 0,613 0,410 0,938
0,370 0,954 0,338 0,313 0,451 0,689
0,407 0,726 0,374 0,315 0,488 0,607
0,430 0,733 0,423 0,503 0,567 0,467
0,450 0,628 0,474 0,423 0,667 0,365
0,481 0,443 0,581 0,145 0,727 0,347
0,540 0,436 0,637 0,250
0,572 0,250 0,664 0,245
0,595 0,390 0,692 0,275










Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx fmg/cm3]
0,087 1,379 0,071 1,363 0,132 0,702
0,176 0,990 0,180 0,745 0,318 0,421
0,248 0,911 0,243 0,557 0,422 0,300
0,311 0,644 0,290 0,591 0,516 0,211
0,372 0,544 0,325 0,463 0,601 0,137
0,430 0,685 0,351 0,617 0,679 0,088
0,483 0,792 0,368 0,630 0,756 0,079
0,521 0,521 0,380 0,390 0,863 0,057
0,549 0,484 0,396 0,394 0,957 0,067
0,577 0,320 0,408 0,975
0,602 0,186 0,422 0,540
0,631 0,473 0,464 0,542
0,658 0,437 0,508 0,255










Table 3: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 80 % of saturation in ME. Skin surface was cleaned 
using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,025 6,585 0,036 8,249 0,041 11,290
0,067 4,855 0,106 6,302 0,135 3,860
0,098 5,297 0,167 5,067 0,232 5,260
0,124 4,500 0,281 2,882 0,315 4,150
0,149 3,115 0,401 3,413 0,397 4,060
0,189 2,700 0,461 2,703 0,459 3,630
0,226 4,927 0,511 1,915 0,501 3,220
0,247 3,485 0,576 1,615 0,545 2,140
0,266 3,540 0,632 2,124 0,587 1,639
0,328 2,072 0,659 2,080 0,618 2,260
0,439 1,698 0,683 1,556 0,640 2,143
0,494 1,696 0,705 1,983 0,682 2,163
0,540 1,350 0,721 2,022 0,721 1,860
0,586 1,568 0,733 2,029 0,740 1,791
0,632 1,168 0,752 1,600 0,760 1,717
0,679 0,821
0,704 1,600
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,085 7,293 0,028 7,487 0,049 7,203
0,169 3,678 0,081 3,735 0,124 5,914
0,271 2,606 0,180 2,511 0,218 3,869
0,362 2,293 0,304 1,570 0,522 2,228
0,451 1,273 0,390 0,864 0,605 1,363
0,521 1,459 0,438 1,350 0,662 1,372
0,569 1,453 0,460 1,125 0,712 1,168
0,601 1,843 0,485 1,015 0,759 1,344
0,627 1,153 0,513 1,050





Table 4: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 80 % of saturation in TCL. Skin surface was cleaned 
using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,073 93,110 0,053 69,257 0,085 103,230
0,190 67,638 0,138 47,096 0,234 98,027
0,290 51,266 0,200 34,508 0,349 83,316
0,383 30,789 0,257 20,348 0,438 73,195
0,448 31,746 0,303 22,400 0,580 57,633
0,499 13,078 0,337 18,783 0,617 44,067
0,541 10,500 0,381 16,738 0,643 30,873
0,575 8,013 0,414 16,600 0,666 21,791
0,609 6,525 0,485 16,982 0,684 30,500
0,638 6,725 0,505 19,300 0,700 27,844
0,660 10,900 0,521 17,025 0,715 22,050
0,681 9,736 0,543 19,509 0,733 11,673
0,704 5,855 0,753 16,233
0,726 5,530 0,768 14,483
0,745 7,763
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,061 80,532 0,053 101,556 0,061 100,263
0,172 45,300 0,131 95,794 0,171 68,274
0,266 35,948 0,190 58,418 0,264 38,329
0,340 29,457 0,254 58,247 0,344 43,704
0,418 21,770 0,310 22,365 0,409 28,843
0,492 14,133 0,353 18,127 0,461 37,547
0,547 8,647 0,388 20,145 0,509 16,253
0,594 8,080 0,420 14,390 0,563 17,805
0,631 13,475 0,453 6,791 0,636 23,094
0,730 3,085 0,484 6,922 0,705 11,269
0,872 2,893 0,526 12,661 0,742 16,280
0,562 17,480 0,770 6,840
0,587 5,655 0,803 4,815




Table 5: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 10 % of saturation in MCT. Skin surface was 
cleaned using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,045 0,259 0,019 0,250 0,061 0,131
0,112 0,146 0,101 0,091 0,147 0,132
0,149 0,067 0,128 0,095 0,200 0,041
0,176 0,057 0,210 0,157 0,263 0,044
0,197 0,067 0,297 0,088 0,401 0,040
0,219 0,229 0,353 0,123 0,468 0,030
0,238 0,100 0,401 0,051 0,546 0,050
0,259 0,044 0,441 0,031
0,285 0,000 0,483 0,092
0,308 0,000 0,513 0,055
0,356 0,052 0,537 0,100
0,415 0,071
0,455 0,060
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,050 0,083 0,069 0,131 0,047 0,086
0,107 0,300 0,167 0,070 0,116 0,033
0,142 0,146 0,212 0,039 0,154 0,098
0,245 0,020 0,238 0,069 0,184 0,031
0,377 0,038 0,257 0,206 0,367 0,010
0,502 0,012 0,286 0,036 0,535 0,014
0,623 0,018 0,347 0,060 0,573 0,032
0,707 0,027 0,369 0,036 0,598 0,000
0,757 0,027 0,390 0,070 0,622 0,000






Table 6: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 10 % of saturation in ME. Skin surface was cleaned 
using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3l x/L Cx [mg/cm3]
0,044 0,808 0,041 0,708 0,056 0,734
0,107 0,775 0,101 0,302 0,139 0,428
0,142 0,444 0,142 0,233 0,203 0,261
0,174 0,580 0,197 0,220 0,318 0,192
0,206 0,256 0,306 0,150 0,448 0,114
0,228 0,775 0,405 0,131 0,515 0,284
0,361 0,126 0,481 0,123 0,561 0,059
0,542 0,141 0,554 0,176 0,631 0,146
0,611 0,189
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,033 0,480 0,069 0,790 0,040 0,572
0,155 0,199 0,174 0,611 0,129 0,216
0,308 0,111 0,242 0,370 0,235 0,188
0,493 0,052 0,337 0,307 0,339 0,130
0,675 0,061 0,450 0,222 0,424 0,042
0,765 0,066 0,518 0,290 0,479 0,080
0,820 0,020 0,572 0,132 0,519 0,030






Table 7: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 1.3 % of saturation in ME. Skin surface was cleaned 
using a dry paper towel post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,045 0,159 0,031 0,056 0,045 0,076
0,109 0,164 0,076 0,051 0,119 0,041
0,147 0,142 0,100 0,040 0,193 0,046
0,221 0,050 0,131 0,038 0,371 0,033
0,392 0,041 0,184 0,014 0,430 0,038
0,542 0,000 0,241 0,030 0,542 0,016
0,601 0,000 0,334 0,025 0,656 0,022
0,661 0,095
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,058 0,069 0,045 0,055 0,038 0,068
0,168 0,026 0,123 0,064 0,097 0,089
0,310 0,044 0,207 0,034 0,186 0,031
0,465 0,055 0,290 0,017 0,309 0,040
0,577 0,009 0,349 0,013 0,425 0,018
0,642 0,000 0,392 0,000 0,496 0,000
0,682 0,000 0,445 0,038 0,521 0,000




Table 8: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 80% of saturation in MCT. Skin surface was cleaned 
using an isopropyl alcohol swab post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,093 0,791 0,052 0,791 0,068 1,172
0,231 0,526 0,130 0,506 0,173 0,533
0,314 0,489 0,182 0,453 0,239 0,500
0,373 0,510 0,222 0,310 0,292 0,328
0,414 0,328 0,256 0,185 0,340 0,235
0,448 0,293 0,289 0,300 0,386 0,265
0,477 0,300 0,315 0,378 0,442 0,158
0,510 0,300 0,341 0,525 0,500 0,144
0,541 0,243 0,363 0,286 0,546 0,350
0,588 0,260 0,404 0,327 0,587 0,236
0,603 0,340 0,685 0,159
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,025 0,353 0,082 0,349 0,037 0,261
0,088 0,174 0,233 0,191 0,110 0,159
0,218 0,089 0,349 0,175 0,189 0,103
0,360 0,100 0,440 0,115 0,341 0,112
0,458 0,059 0,530 0,091 0,506 0,090
0,550 0,038 0,610 0,100 0,687 0,038
0,637 0,038 0,671 0,105 0,865 0,050
0,762 0,037 0,712 0,050 0,939 0,060
0,742 0,000 0,990 0,028
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Table 9: BMV concentrations [mg/cm3] across the SC (x/L) following a 2-hour 
application of the drug at 80% of saturation in ME. Skin surface was cleaned 
using an isopropyl alcohol swab post-application of gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,069 1,991 0,024 3,688 0,033 3,365
0,180 0,788 0,068 1,064 0,086 1,792
0,261 0,329 0,101 2,588 0,147 1,200
0,360 0,202 0,127 1,470 0,254 0,705
0,464 0,091 0,166 1,694 0,425 0,548
0,537 0,108 0,216 1,322 0,603 0,348
0,576 0,255 0,289 0,981 0,722 0,175
0,639 0,151 0,372 0,920 0,788 0,600
0,703 0,200 0,443 0,578
0,738 0,463 0,492 0,990
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,075 1,943 0,058 1,205 0,046 1,577
0,262 1,086 0,212 0,616 0,150 1,076
0,444 0,580 0,371 0,370 0,252 0,679
0,581 0,422 0,509 0,284 0,361 0,437
0,703 0,169 0,629 0,143 0,484 0,251
0,807 0,148 0,718 0,131 0,559 0,347
0,913 0,149 0,776 0,313 0,649 0,104






Table 10: BMV concentrations [mg/cm3] across the SC (x/L) following a 2- 
hour application of the drug at 80% of saturation in MCT. Skin surface was 
cleaned using a dry paper towel post-application of un-gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,047 1,227 0,022 1,025 0,049 0,939
0,128 0,709 0,055 0,567 0,115 0,733
0,185 0,409 0,075 0,400 0,162 0,517
0,230 0,365 0,095 0,233 0,220 0,358
0,274 0,423 0,120 0,213 0,265 0,279
0,316 0,211 0,138 0,400 0,299 0,291
0,349 0,107 0,151 0,200 0,343 0,252
0,374 0,590 0,171 0,150 0,386 0,155
0,389 0,825 0,195 0,129 0,420 0,264
0,398 0,300 0,213 0,300 0,456 0,108
0,414 0,510 0,238 0,245 0,482 0,229
0,444 0,242 0,273 0,150 0,506 0,145
0,475 0,250 0,298 0,117 0,532 0,325
0,489 0,325 0,349 0,414 0,556 0,056
0,508 0,443 0,404 0,213





Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,027 0,576 0,044 0,361 0,054 0,648
0,118 0,220 0,115 0,161 0,135 0,381
0,243 0,111 0,163 0,115 0,181 0,264
0,347 0,081 0,202 0,092 0,235 0,200
0,561 0,037 0,266 0,118 0,290 0,150
0,784 0,047 0,313 0,084 0,340 0,112
0,901 0,041 0,389 0,121 0,492 0,038




Table 11: BMV concentrations [mg/cm3] across the SC (x/L) following a 2- 
hour application of the drug at 80% of saturation in ME. Skin surface was 
cleaned using a dry paper towel post-application of un-gelled vehicles.
Volunteer 1 Volunteer 2 Volunteer 3
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,035 6,888 0,021 6,229 0,045 4,636
0,085 6,167 0,052 3,586 0,126 2,792
0,118 3,382 0,071 3,300 0,248 1,858
0,164 2,567 0,104 1,431 0,412 0,991
0,219 2,016 0,178 1,250 0,542 0,523
0,265 1,068 0,261 1,527 0,676 0,471
0,294 1,556 0,339 1,687 0,771 1,573
0,341 1,036 0,429 1,443 0,819 0,479
0,409 0,655 0,487 1,333
0,460 2,005 0,529 1,037
0,490 3,400 0,563 2,475
Volunteer 4 Volunteer 5 Volunteer 6
x/L Cx [mg/cm3] x/L Cx [mg/cm3] x/L Cx [mg/cm3]
0,030 4,644 0,117 1,033 0,036 3,464
0,105 2,159 0,339 0,475 0,093 2,553
0,217 1,120 0,513 0,250 0,145 1,552
0,338 0,858 0,632 0,119 0,216 1,147
0,442 0,503 0,744 0,075 0,291 0,893
0,532 0,604 0,846 0,092 0,361 0,681
0,647 0,636 0,910 0,033 0,555 0,520




Table 12: DPK parameter deduced from the BMV distribution profiles 
following a 2-hour application. BMV concentration was adjusted to different 
levels of saturation in several vehicles. Skin surface was cleaned using a dry 
paper towel post-application of gelled vehicles.
K
Volunteer MCT 2h 80% ME 2h 80% TCL2h80% MCT 2h 10% ME 2h 10% ME 2h 1.3%
1 0,96 0,69 1,12 1,24 0,73 1,27
2 0,62 0,79 0,67 0,86 0,57 0,38
3 1,22 0,96 1,29 0,69 0,58 0,45
4 0,83 0,77 0,86 0,98 0,44 0,45
5 0,80 0,68 1,28 0,66 0,68 0,43
6 0,54 0,78 1,02 0,40 0,49 0,59
D/L2 F1 /hi
Volunteer MCT 2h 80% ME 2h 80% TCL 2h80% MCT 2h 10% ME 2h 10% ME 2h 1.3%
1 0,058 0,076 0,032 0,012 0,032 0,026
2 0,059 0,075 0,033 0,068 0,010 0,025
3 0,066 0,066 0,097 0,032 0,031 0,082
4 0,080 0,039 0,030 0,025 0,012 0,057
5 0,045 0,023 0,019 0,048 0,052 0,037
6 0,046 0,060 0,044 0,031 0,013 0,022
AUC [mg/cm3l
Volunteer MCT 2h 80% ME 2h 80% TCL 2h80% MCT 2h 10% ME 2h 10% ME 2h 1.3%
1 0,49 2,65 32,17 0,05 0,25 0,05
2 0,39 3,03 19,43 0,07 0,11 0,01
3 0,81 3,48 57,27 0,04 0,19 0,03
4 0,59 2,23 23,98 0,05 0,09 0,02
5 0,45 1,54 28,21 0,05 0,29 0,02
6 0,31 2,75 33,99 0,02 0,11 0,02
Cs,sc mg/ml]
Volunteer ME 2h 80% ME 2h 10% ME 2h 1.3% MCT 2h 80% MCT 2h 10% TCL 2h80%
1 8,12 8,54 14,84 1,70 2,59 141,25
2 9,29 6,70 4,43 1,30 1,81 84,16
3 11,19 6,80 5,22 2,56 1,44 162,04
4 9,01 5,10 5,25 1,74 2,06 108,16
5 7,97 7,97 4,98 1,67 1,38 161,78
6 9,18 5,71 6,96 1,14 0,85 129,02
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Table 13: DPK parameter deduced from the BMV distribution profiles 
following a 6-hour application. BMV concentration was adjusted to 80% of the 
saturation level in MCT and ME. Skin surface was cleaned using a dry paper 
towel post-application of gelled vehicles.
MCT 6h 80%
Volunteer K D/L2 [1/h] Cs,sc [mg/ml] AUC [mg/cm3]
1 0,88 0,024 1,85 0,60
2 0,48 0,044 1,00 0,38
3 0,77 0,044 1,62 0,61
4 0,92 0,025 1,93 0,63
5 0,93 0,055 1,96 0,77
6 0,65 0,029 1,37 0,47
ME 6h 80%
Volunteer K D/L2 [1/h] Cs,sc [mg/ml] AUC [mg/cm3]
1 0,69 0,035 8,04 2,86
2 0,85 0,026 9,93 3,27
3 0,83 0,032 9,66 3,38
4 1,29 0,043 15,03 5,59
5 1,11 0,023 12,95 4,09
6 1,30 0,056 15,22 5,87
Table 14: DPK parameter deduced from the BMV distribution profiles 
following a 2-hour application. BMV concentration was adjusted to 80% of the 
saturation level in MCT and ME. Skin surface was cleaned using an isopropyl 
alcohol swab post-application of gelled vehicles.
MCT 2h 80%
Volunteer K D/L2 [1/h] Cs,sc [mg/ml] AUC [mg/cm3]
1 0,51 0,074 1,07 0,35
2 0,42 0,046 0,89 0,24
3 0,73 0,023 1,53 0,30
4 0,18 0,022 0,38 0,07
5 0,22 0,055 0,46 0,14
6 0,13 0,073 0,27 0,09
ME 2h 80%
Volunteer K D/L2 [1/h] Cs,sc [mg/ml] AUC [mg/cm3]
1 0,31 0,007 3,63 0,39
2 0,29 0,031 3,42 0,76
3 0,40 0,006 4,68 0,47
4 0,24 0,042 2,80 0,72
5 0,13 0,051 1,50 0,42
6 0,18 0,031 2,09 0,47
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Table 15: DPK parameter deduced from the BMV distribution profiles 
subsequent to a 2-hour application. BMV concentration was adjusted to 80% 
of the saturation level in MCT and ME. Skin surface was cleaned using a dry 
paper towel post-application of un-gelled (liquid) vehicles.
MCT 2h 80%
Volunteer K D/L2 M/hl Cs,sc [mg/ml] AUC [mg/cm3]
1 0,58 0,046 1,22 0,33
2 0,46 0,008 0,96 0,11
3 0,57 0,025 1,19 0,24
4 0,38 0,006 0,79 0,08
5 0,15 0,045 0,32 0,09
6 0,46 0,011 0,97 0,13
ME 2h 80%
Volunteer K D/L2 f1/hl Cs,sc fmg/ml] AUC [mg/cm3l
1 0,77 0,014 9,03 1,34
2 0,42 0,051 4,88 1,37
3 0,48 0,033 5,66 1,30
4 0,52 0,009 6,13 0,73
5 0,14 0,036 1,70 0,41
6 0,40 0,013 4,65 0,68
Table 16: Amount of BMV in the SC as a function of time after application of 
BMV in MCT at 80% of the saturation level. For the uptake phase, 
formulations were removed at 2, 4 and 6 hours and subsequently tape- 
stripped. For the elimination phase, formulations were maintained to the skin 
for 6 hours, subsequently removed, and the SC was stripped after a further 2, 
6 and 24 hours.
Amount of BMV in the SC [ug/cm2l
time [hi Volunteerl Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6
0 0 0 0 0 0 0
2 0,83 0,61 0,68 0,57 0,90 0,74
4 0,91 0,66 0,85 0,67 1,34 0,72
6 1,70 0,80 1,02 1,07 1,33 0,98
8 1,10 0,57 0,84 0,65 0,92 0,54
12 1,00 0,46 0,69 0,61 0,75 0,50
30 0,28 0,41 0,58 0,29 0,24 0,34
AUC [ug*h/cm2] 22,87 13,99 19,75 15,32 19,41 14,32
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Table 17: Amount of BMV in the SC as a function of time after application of 
BMV in ME at 80% of the saturation level. For the uptake phase, formulations 
were removed at 2, 4 and 6 hours and subsequently tape-stripped. For the 
elimination phase, formulations were maintained to the skin for 6 hours, 
subsequently removed, and the SC was stripped after a further 2, 6 and 24 
hours.
Amount of BMV in the SC fug/cm2]
time [h] Volunteerl Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6
0 0 0 0 0 0 0
2 7,10 4,27 5,44 7,99 7,16 4,22
4 5,21 4,89 6,11 7,61 5,19 9,65
6 7,94 8,08 6,68 7,23 4,71 4,38
8 3,51 3,56 4,16 4,81 3,90 3,54
12 3,15 2,76 1,91 4,41 3,41 1,81
30 2,21 1,04 0,96 1,04 1,01 0,94
AUC [pg*h/cm2] 98,47 80,61 73,15 109,97 85,26 71,27
Table 18a: Chromameter a-scale raw data for a volunteer following a 4-hour 
dose duration of BMV at different concentrations in ME. BL = baseline.
Measurement 
time [h] Control 1,2 mg/ml 0,6 mg/ml 0,3 mg/ml 0,15 mg/ml 0,07 mg/ml 0,04 mg/ml
BL (-5) 7,43 8,32 7,01 8,45 6,39 7,52 6,97
0 6,60 6,77 5,28 7,46 6,00 6,97 6,16
2 7,70 6,27 5,07 6,70 5,68 6,70 6,42
4 7,87 6,49 5,06 6,52 5,59 6,54 6,79
6 7,78 5,96 5,27 6,53 5,78 6,69 6,67
19 7,05 6,62 6,20 7,13 6,05 7,09 6,86
24 7,85 8,17 6,95 7,48 6,34 7,49 7,06
Table 18b: Baseline-adjusted a-scale data for a volunteer following a 4-hour 
dose duration of BMV at different concentrations in ME.
Measurement 
time [h] Control 1,2 mg/ml 0,6 mg/ml 0,3 mg/ml 0,15 mg/ml 0,07 mg/ml 0,04 mg/ml
BL (-5) 0 0 0 0 0 0 0
0 -0,83 -1,55 -1,73 -0,99 -0,39 -0,55 -0,81
2 0,27 -2,05 -1,94 -1,75 -0,71 -0,82 -0,55
4 0,44 -1,83 -1,95 -1,93 -0,80 -0,98 -0,18
6 0,35 -2,36 -1,74 -1,92 -0,61 -0,83 -0,30
19 -0,38 -1,70 -0,81 -1,32 -0,34 -0,43 -0,11
24 0,42 -0,15 -0,06 -0,97 -0,05 -0,03 0,09
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Table 18c: Baseline-adjusted, control site-corrected a-scale data and 
AARC(0-24) for a volunteer following 4-hour dose duration of BMV at different 
concentrations in ME.
Measurement 
time [h] Control 1,2 mg/ml 0,6 mg/ml 0,3 mg/ml 0,15 mg/ml 0,07 mg/ml 0,04 mg/ml
BL (-5) 0 0 0 0 0 0 0
0 0 -0,72 -0,90 -0,16 0,44 0,28 0,02
2 0 -2,32 -2,21 -2,02 -0,98 -1,09 -0,82
4 0 -2,27 -2,39 -2,37 -1,24 -1,42 -0,62
6 0 -2,71 -2,09 -2,27 -0,96 -1,18 -0,65
19 0 -1,32 -0,43 -0,94 0,04 -0,05 0,27
24 0 -0,57 -0,48 -1,39 -0,47 -0,45 -0,33
AARC(0-24) -43,53 -30,85 -37,90 -12,12 -15,22 -6,06
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Table 19: Baseline-adjusted, control site-corrected a-scale data following 
different dose durations of BMV at 80% of the saturation level in MCT.
DD = 2h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -0,50 -1,30 -1,82 -1,94 -0,98 -0,77
2 -0,54 -1,26 -1,25 -1,37 -0,90 -0,50
3 -0,52 -0,58 -2,28 -3,05 -1,96 -0,60
4 -0,75 -1,23 -1,62 -2,50 -1,05 -1,06
5 -0,40 -1,15 -2,81 -2,56 -0,40 -0,53
6 -0,55 -2,54 -2,90 -2,60 -1,25 -0,53
DD = 3h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 0,00 -1,72 -1,48 -2,50 -0,97 0,00
2 -2,89 -3,13 -3,38 -3,14 -0,40 0,00
3 -0,28 -0,24 -2,48 -2,15 -1,24 -1,06
4 0,00 0,27 -1,00 -2,25 -1,18 -0,81
5 -1,04 -1,77 -2,83 -2,94 -0,87 -0,75
6 -1,04 -2,28 -3,03 -3,01 -1,33 -0,60
DD = 4h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -1,40 -2,89 -2,23 -2,82 -0,80 -0,19
2 -2,33 -3,49 -3,75 -3,77 -1,35 -0,33
3 -1,59 -1,18 -2,06 -3,03 -1,38 -1,69
4 -1,63 -0,65 -1,99 -2,99 -1,67 -0,70
5 -1,43 -2,17 -2,88 -3,05 -0,57 -0,48
6 -1,20 -1,15 -1,59 -1,89 -0,86 -0,46
DD = 5h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -1,76 -3,72 -2,56 -3,51 -1,79 -0,82
2 -1,89 -1,94 -2,70 -2,97 -0,15 -0,05
3 -1,66 -1,42 -3,24 -2,80 -1,30 -0,56
4 -1,69 -2,30 -2,84 -3,32 -1,13 -0,69
5 -1,85 -2,45 -2,05 -2,66 -0,68 -0,14
6 -0,56 -2,27 -2,28 -2,96 -1,07 -1,00
DD = 6h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -2,54 -2,33 -3,09 -3,59 -1,28 -0,37
2 -1,98 -2,14 -2,89 -3,26 -0,36 -0,55
3 -1,51 -0,98 -1,87 -2,18 -1,07 -0,17
4 -1,76 -2,83 -2,77 -3,37 -2,19 -1,00
5 -1,55 -2,41 -2,57 -2,96 -0,61 -0,55
6 -3,00 -3,21 -3,15 -3,51 -1,29 -0,38
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Table 20: Baseline-adjusted, control site-corrected a-scale data following 
different dose durations of BMV at 80% of the saturation level in ME.
DD = 2h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -1,45 -1,72 -3,83 -3,70 -1,68 -0,76
2 -1,27 -1,41 -2,15 -2,57 -0,44 -0,12
3 -1,02 -1,10 -1,85 -2,40 -1,67 -1,07
4 -0,22 -1,46 -2,06 -3,49 -1,56 -0,14
5 -0,82 -1,75 -2,76 -3,81 -1,17 -0,21
6 -0,80 -1,94 -1,43 -2,37 -1,08 -0,63
DD = 3h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 0,00 -0,42 -2,80 -2,61 -1,15 0,00
2 -0,60 -2,48 -2,67 -3,65 -0,93 -0,75
3 0,00 -1,88 -1,37 -2,14 -0,59 -0,60
4 0,00 -1,54 -2,14 -3,51 -1,61 -0,59
5 -1,12 -2,72 -3,67 -3,55 -1,43 -1,06
6 0,00 -1,25 -1,67 -2,19 -0,85 -0,56
DD = 4h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -0,52 -2,22 -3,08 -3,48 -1,72 -0,12
2 -2,05 -3,13 -3,11 -3,22 -0,68 -0,70
3 -0,30 -2,16 -1,82 -2,91 -1,29 -0,77
4 -0,90 -1,51 -1,79 -2,18 -0,57 -0,40
5 -1,93 -2,33 -3,02 -3,40 -1,17 -0,84
6 -2,03 -1,77 -2,87 -3,35 -1,33 -0,47
DD = 5h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -2,22 -1,90 -3,47 -3,99 -0,54 0,00
2 -2,62 -3,28 -3,17 -3,26 -0,80 -0,89
3 -1,40 -3,40 . -2,51 -2,44 -2,10 -0,31
4 -0,21 -1,87 -2,65 -3,60 -1,38 0,00
5 -2,68 -2,76 -3,08 -3,15 -0,82 -0,67
6 -1,58 -2,01 -2,68 -3,22 -1,02 -0,35
DD = 6h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -2,15 -2,56 -2,86 -3,06 -0,97 -0,40
2 -2,91 -3,02 -2,97 -3,13 -1,00 -0,37
3 -1,31 -3,13 -3,00 -3,58 -1,72 -0,75
4 -2,37 -3,09 -3,62 -4,39 -2,11 -1,11
5 -2,04 -1,95 -3,04 -3,58 -0,17 -0,23
6 -2,66 -2,11 -2,90 -3,69 -0,98 -0,98
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Table 21: Baseline-adjusted, control site-corrected a-scale data following 
different dose durations of BMV at 80% of the saturation level in TCL.
DD = 2h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 0,00 0,00 -0,48 -3,44 -0,81 0,00
2 0,00 -1,40 -1,42 -1,27 0,00 0,00
3 -0,50 -2,02 -1,61 -1,47 0,00 0,00
4 -0,28 -1,58 -2,85 -1,49 -0,39 -0,17
5 0,00 -1,25 -1,81 -2,90 -0,47 -0,57
6 0,00 -1,82 -1,68 -2,07 -1,18 -0,06
DD = 3h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 0,00 -0,29 -1,39 -3,50 -0,62 0,00
2 -1,15 -1,15 -2,24 -1,57 0,00 0,00
3 -1,04 -2,80 -2,15 -1,96 -0,48 0,00
4 -0,10 -1,41 -2,28 -1,51 -0,82 -0,51
5 -0,68 -0,51 -1,41 -1,87 0,00 0,00
6 -0,29 -2,46 -2,38 -2,24 -1,30 -0,90
DD = 4h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -0,62 -1,88 -1,72 -3,75 -1,66 -0,10
2 -1,39 -0,74 -1,47 -1,34 -0,40 -0,20
3 -1,61 -3,11 -2,08 -2,25 -1,60 -0,20
4 -1,41 -1,78 -3,65 -2,10 -0,50 -0,10
5 -0,98 -0,92 -1,12 -2,21 -0,19 -0,50
6 -0,71 -2,40 -1,85 -1,78 -0,39 -0,10
DD = 5h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -1,86 -2,27 -3,56 -3,85 -1,39 0,00
2 -2,90 -2,77 -2,38 -2,76 0,00 0,00
3 -2,84 -3,30 -2,78 -2,49 -0,26 -0,20
4 -2,13 -1,76 -3,20 -2,71 -0,69 -0,72
5 -0,88 -1,92 -1,79 -2,34 0,00 0,00
6 -1,07 -2,59 -2,01 -2,60 -0,25 -0,48
DD = 6h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 -1,70 -2,23 -3,67 -3,70 -0,65 0,00
2 -2,94 -2,82 -2,91 -2,79 0,00 0,00
3 -3,10 -3,58 -3,50 -3,33 -0,87 -0,53
4 -0,20 -2,45 -2,51 -3,12 -0,15 -0,30
5 -1,58 -1,74 -2,18 -3,34 -0,44 -0,25
6 -1,17 -2,47 -1,60 -2,52 -0,34 0,00
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Table 22: Baseline-adjusted, control site-corrected a-scale data following 
different dose durations of BMV at 80% of the saturation level in LMO.
DD = 2h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 0,78 0,62 0,67 -0,08 0,37 -1,09
2 0,85 -1,19 -2,41 -0,15 -0,12 -0,58
3 0,90 0,63 -1,71 -0,89 0,38 -0,10
4 0,05 0,18 -0,09 -0,74 -1,20 -0,17
5 0,00 0,73 -0,10 -0,02 -1,85 -0,52
6 0,84 -0,05 -0,08 -0,25 -0,61 -0,69
DD = 3h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 0,00 0,00 -0,31 -1,02 0,00 -0,88
2 0,00 -2,01 -2,13 -1,30 0,00 -0,92
3 -0,49 -0,38 -2,68 -2,75 -1,34 -0,76
4 -0,57 0,00 -0,16 -0,06 -1,04 -0,47
5 0,00 -0,24 -1,56 -1,91 -2,00 -0,31
6 -0,98 -0,49 -1,22 -0,60 -0,19 -0,44
DD = 4h
Volunteer Oh 2 h 4 h 6 h 19 h 24 h
1 0,82 0,44 -0,49 -0,06 -1,74 -0,66
2 1,10 -1,33 -0,90 -1,44 -0,98 -0,65
3 -1,69 -0,54 -1,09 -1,07 -1,19 -1,18
4 1,36 -0,31 -1,18 -1,27 -0,60 -0,64
5 -0,45 0,15 -0,97 -1,44 -0,71 -0,63
6 0,26 -0,68 -1,69 -1,86 -2,06 -1,20
DD = 5h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 0,00 0,00 -0,22 -0,80 0,09 0,10
2 0,00 -1,11 -1,51 -1,56 -0,68 -0,28
3 -0,76 -0,89 -1,22 -1,56 -0,62 -1,77
4 -0,66 -0,65 -0,94 -2,30 -0,78 -0,35
5 -1,19 -0,71 -1,46 -1,46 -0,86 -0,88
6 -0,74 -2,14 -2,15 -2,00 0,02 -0,69
DD = 6h
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -0,75 -1,34 -1,76 -2,15 -1,25 -1,37
2 0,00 -1,03 -2,98 -1,12 -0,56 -0,09
3 -0,56 -1,57 -1,76 -3,02 -0,48 -1,05
4 -0,80 -0,88 -1,61 -1,69 -0,85 -1,39
5 -0,03 -0,41 -0,89 -0,82 -1,60 -0,97
6 -2,39 -2,54 -2,09 -1,83 -0,15 -0,62
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Table 23: Baseline-adjusted, control site-corrected a-scale data following a 4- 
hour dose durations of BMV at different levels of the saturation level in ME.
10,43%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 -1,17 -1,60 -0,52 -0,72 -1,35 -2,23 0,00 -0,82
2 -1,40 -1,94 -2,26 -2,32 -3,02 -2,91 -1,54 -1,84
4 -2,31 -2,98 -2,93 -2,27 -2,92 -2,60 -2,99 -2,18
6 -2,66 -3,28 -3,24 -2,71 -3,41 -2,87 -3,74 -2,28
19 -2,47 -1,32 -1,60 -1,32 -1,12 -0,61 -1,17 -0,58
24 -0,56 -0,68 -0,15 -0,57 0,00 -0,19 -0,36 -0,63
5,21%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 -0,63 -0,30 -0,03 -0,90 -1,63 -1,29 0,00 -0,57
2 -1,67 -1,64 -0,91 -2,21 -3,44 -2,57 -1,25 -1,75
4 -1,82 -2,49 -1,46 -2,39 -3,15 -2,73 -3,49 -2,07
6 -2,56 -2,22 -2,83 -2,09 -3,32 -2,80 -3,67 -2,73
19 -0,42 -0,96 -0,95 -0,43 -0,18 -0,91 -0,90 -0,54
24 -1,14 -0,40 -0,48 -0,48 -0,10 -0,35 -0,61 -0,68
2,61%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 0,00 0,00 -0,07 -0,16 -0,81 -1,02 0,00 0,00
2 -0,02 -0,32 -0,70 -2,02 -2,82 -2,66 -0,49 -0,96
4 -0,13 -2,00 -1,91 -2,37 -3,44 -2,43 -2,30 -1,26
6 -1,58 -1,97 -2,20 -2,27 -3,07 -2,01 -2,49 -1,39
19 -0,19 -0,32 -0,57 -0,94 -1,88 -0,69 -0,33 -0,25
24 -0,64 0,00 0,00 -1,39 -0,67 -0,33 0,00 0,00
1,30%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 -0,23 0,00 0,00 0,00 -0,96 -1,74 0,00 -0,21
2 -0,47 -0,32 -0,98 -0,93 -2,24 -2,34 0,03 -1,09
4 -0,34 -1,92 -1,96 -1,19 -1,93 -2,68 -2,79 -1,33
6 -1,36 -1,68 -2,88 -0,91 -1,99 -2,46 -2,41 -1,57
19 -0,44 -0,12 0,00 0,00 -0,24 -0,57 -0,52 -0,15
24 -0,92 0,00 0,00 -0,42 -0,02 -0,07 0,00 0,00
0,64%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 0,00 0,00 0,00 0,00 -0,70 -0,13 0,00 0,00
2 -0,21 -0,64 0,00 -1,08 -1,34 -1,15 0,00 -0,95
4 -0,42 -1,58 -0,30 -1,41 -1,10 -1,54 -2,34 -1,27
6 -1,26 -1,16 -0,73 -1,17 -0,95 -1,25 -2,24 -1,35
19 -0,22 -0,43 -0,16 -0,04 -0,73 -0,06 -0,76 -0,20
24 -0,54 0,00 0,00 -0,44 -0,57 0,00 -0,60 0,00
0,32%
Time [h] Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 Volunteer 5 Volunteer 6 Volunteer 7 Volunteer 8
0 -0,85 0,00 0,00 0,00 0,00 -1,03 0,00 -0,45
2 -1,17 -1,51 0,00 -0,64 -0,41 -1,03 0,00 -1,13
4 -0,55 -2,41 -0,04 -0,44 -0,42 -1,15 -2,65 -0,79
6 -0,61 -1,60 -0,25 -0,47 -0,63 -0,92 -2,22 -1,40
19 -0,82 -1,25 -0,12 0,00 -0,27 -0,19 -1,07 -0,77
24 -0,37 -0,10 0,00 -0,15 0,00 0,00 -0,79 -0,40
175
Appendix
Table 24: Baseline-adjusted, control site-corrected a-scale data following a 4- 
hour dose durations of BMV at different levels of the saturation level in MCT.
io%
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -0,90 -2,64 -1,72 -2,12 -0,48 -0,77
2 0,00 -0,68 -1,21 -1,21 -1,04 -0,45
3 -1,28 -1,11 -0,88 -1,22 -1,09 -0,34
4 -1,41 -1,22 -0,70 -1,56 -1,42 -0,36
5 0,00 -1,12 -0,91 -2,20 -0,40 -0,04
6 -1,20 -0,69 -1,63 -1,51 -0,55 -0,12
1,30%
Volunteer 0 h 2 h 4 h 6 h 19 h 24 h
1 -0,85 -1,46 -0,44 -1,81 -0,93 -0,14
2 -0,71 -0,28 -1,27 -0,65 -1,40 -0,07
3 -0,10 0,00 -0,81 -0,71 -1,07 -0,20
4 -0,03 -0,34 -0,54 -1,27 -0,48 -0,51
5 -0,39 -0,66 -0,47 -1,42 -0,70 -0,80
6 0,00 -0,75 -0,68 -1,57 -0,52 -0,67
7 0,00 -0,58 -0,93 -0,54 -0,44 -0,46
176
Appendix
Table 25: Area under the response curve values (AARC) derived from the 
blanching response versus time profiles of BMV after different dose durations 
(DD). BMV concentration was adjusted to 80% of the saturation level.
AARC DD 2h
Volunteer LMO MCT ME TCL
1 3,37 -32,04 -57,32 -34,05
2 -10,01 -25,19 -31,93 -15,17
3 -4,77 -48,26 -42,63 -18,79
4 -16,55 -37,30 -47,83 -24,25
5 -16,84 -32,45 -49,47 -33,53
6 -8,51 -43,51 -36,61 -33,30
AARC DD 3h
Volunteer LMO MCT ME TCL
1 -10,47 -33,88 -36,37 -35,19
2 -20,33 -43,06 -48,52 -19,71
3 -41,20 -35,66 -29,36 -29,96
4 -11,88 -30,98 -49,65 -27,46
5 -36,70 -42,00 -56,05 -18,55
6 -11,71 -47,71 -31,32 -40,72
AARC DD 4h
Volunteer LMO MCT ME TCL
1 -17,01 -40,47 -53,00 -51,14
2 -24,62 -58,06 -46,55 -19,96
3 -26,54 -47,44 -43,62 -43,77
4 -18,15 -46,12 -29,98 -32,77
5 -20,86 -40,74 -50,76 -24,60
6 -39,97 -29,75 -49,58 -26,32
AARC DD 5h
Volunteer LMO MCT ME TCL
1 -5,38 -58,81 -47,75 -54,91
2 -23,76 -34,92 -49,40 -33,90
3 -26,69 -45,08 -51,20 -36,52
4 -28,99 -48,77 -48,67 -40,39
5 -26,42 -37,27 -47,04 -25,85
6 -41,73 -43,99 -45,17 -33,22
AARC DD 6h
Volunteer LMO MCT ME TCL
1 -37,75 -52,75 -45,67 -47,10
2 -21,69 -41,11 -48,29 -35,33
3 -36,82 -33,62 -57,78 -51,39
4 -29,58 -60,45 -70,48 -35,62
5 -25,61 -40,58 -40,98 -39,06
6 -28,28 -54,61 -51,63 -31,27
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Table 26: Area under the response curve values (AARC) derived from the 
blanching response versus time profiles of BMV at different levels of 
saturation in ME after a 4-hour dose duration.
AARC ME
Volunteer 10,43% 5,21% 2,61% 1,30% 0,64% 0,32%
1 -52,17 -33,44 -15,46 -18,31 -14,04 -17,17
2 -49,62 -34,85 -22,30 -18,16 -17,01 -31,34
3 -49,98 -35,75 -26,92 -27,48 -7,51 -3,03
4 -43,53 -30,85 -37,90 -12,12 -15,22 -6,06
5 -48,89 -41,58 -54,95 -26,44 -20,70 -8,82
6 -40,74 -41,96 -33,31 -35,54 -15,43 -14,00
7 -48,54 -46,63 -27,23 -28,28 -29,82 -33,56
8 -32,76 -35,25 -17,12 -18,18 -16,37 -22,72
Table 27: Area under the response curve values (AARC) derived from the 
blanching response versus time profiles of BMV at different levels of 
saturation in MCT after a 4-hour dose duration.
AARC MCT
Volunteer 10% 1,30% 0,64%
1 -31,77 -29,45 -6,73
2 -23,34 -21,46 -12,14
3 -25,07 -17,18 -6,03
4 -30,63 -16,91 -6,50
5 -24,26 -24,10 -9,75
6 -22,42 -23,49 -6,75
7 -12,18
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